



**Francisca Sofia Rodrigues de Freitas Pereira**

Licenciada em Genética e Biotecnologia

**Blocking tumor exosome release using  
nanovectorization systems**

Dissertação para obtenção do Grau de Mestre em  
Genética Molecular e Biomedicina

Orientador: Maria Alexandra Nuncio de Carvalho Ramos Fernandes, Professora  
Doutora, FCT/UNL

Co-orientador: Pedro Viana Baptista, Professor Doutor, FCT/UNL

Júri:

Presidente: Professor Doutor José Paulo Nunes de Sousa Sampaio

Arguente: Professora Doutora Paula Alexandra Quintela Videira

Vogal: Professora Doutora Alexandra Nuncio de Carvalho Ramos Fernandes



FACULDADE DE  
CIÊNCIAS E TECNOLOGIA  
UNIVERSIDADE NOVA DE LISBOA

Lisboa, 2015



**UNIVERSIDADE NOVA DE LISBOA**  
**FACULDADE DE CIÊNCIAS E TECNOLOGIA**  
**DEPARTAMENTO DE CIÊNCIAS DA VIDA**

Francisca Sofia Rodrigues de Freitas Pereira

**Blocking tumor exosome release using  
nanovectorization systems**

Dissertação apresentada para obtenção do Grau de  
Mestre em Genética Molecular e Biomedicina, pela  
Universidade Nova de Lisboa, Faculdade de  
Ciências e Tecnologia

**Orientadora:**

Professora Doutora Alexandra Fernandes (FCT/UNL)

**Co-orientador:**

Professor Doutor Pedro Viana Baptista (FCT/UNL)

**Lisboa 2015**



## **Blocking tumor exosome release using nanovectorization systems**

Copyright © Francisca Sofia Rodrigues de Freitas Pereira, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa.

A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou que venha a ser inventado, e de a divulgar através de repositórios científicos e de admitir a sua cópia e distribuição com objectivos educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e editor.



## ACKNOWLEDGMENTS

At first, I want to thank my supervisors Professor Alexandra Fernandes and Professor Pedro Viana Baptista for the opportunity they gave me to work on these laboratories and for all the help they provided me along the way. Thank you for being demanding with me, it made me realize that I can do much more than I thought and made me learn a lot.

To Catarina Rodrigues, who guided me through my work since the beginning, thank you for all the patience, all the advices and all the help when I needed.

Thanks to my colleagues here Carolina, João, Joana, Luís Raposo, Pedro, Sílvia, Sofia and Soraia for all the help, all the laughs, all the jokes and for making easier to surpass those not so good moments. Thanks to my colleagues of 315 for all the help and for being so fun. You are a very nice group and I really enjoyed working with you.

To Marta Fernandes, thank you for the company and the help in those months you were at the lab. I really liked to work with you and I hope you have learnt something with me.

For all the weekly dinners, for being my “big brothers” here, telling me all the funny stories and for all the company, I want to thank to the boys and girls “from Vila Real”. We created a very good group here and I am very happy for that!

To Lili, Mariana and David thank you a lot for all the dinners, all the talks, the laughs. It is a great friendship we started and I know no matter the distance we will keep talking!

To my friends, for being always there, always making me laugh and feel better. Although we just see each other twice a month or so, I know we will always be us! Special thanks to my best friends Tomás, Jony, Lu and Gonçalo for all the fun and all the care!

To my oldest friend Mariana, thank you for all the help and despite we don't talk too much I know I can count on you. Those times when we lived together in Lisbon were good times! To Ângela, for the company here in Lisbon!

I want to express my gratitude to my grandparents, who always believed in me, always supported me and called me every Wednesday night and every weekend to cheer me up and feel a little bit closer to home. Thanks to my grandmother and all my big family for being so united and so fun!

At last, I want to thank to the most important persons in my life: my little sister for annoying me in a way that only she knows!, for all the “bullying” she gives me and all the good times we have together and I am sorry for not being always around; to my parents, my greatest supporters, thank you for always believing in me and making me believe, for not letting me give up of anything and for all the effort they made so I could get here. Thank you so much!





## RESUMO

Os exossomas são pequenas vesículas membranares secretados por muitas células, normais ou malignas, e são encontrados em vários fluídos como saliva, plasma e leite materno. Na última década, o interesse nestas vesículas tem vindo a crescer uma vez que foi descoberto que, para além de terem funções benéficas como a remoção de detritos e proteínas desnecessárias durante o processo de maturação celular, os exossomas podem também interagir com outras células e transferir informação entre elas, podendo promover o avanço de doenças como o cancro. A presente tese teve como objetivo utilizar nanopartículas de ouro como veículos para o silenciamento génico, numa tentativa de reduzir a secreção de exossomas por parte das células tumorais, regulada pela proteína Rab27a, assim como comparar a quantidade de exossomas secretados entre duas linhas tumorais mamárias, MCF7 e MDA. Variações na expressão do gene *RAB27A* foram avaliadas por PCR quantitativa em tempo real e, como esperado, foi demonstrado haver uma diminuição nessa expressão. Os exossomas foram isolados e purificados por dois métodos diferentes, ultracentrifugação e o Kit comercial *ExoQuick™ Solution*, sendo depois caracterizados por *Western blot*. Foi demonstrado que *ExoQuick™ Solution* é mais eficiente para o isolamento de exossomas e também que as células MDA secretam uma maior quantidade dos mesmos. Um ensaio adicional foi realizado em que os exossomas isolados a partir das células MCF7 foram incubados com uma linha celular normal de brônquios e traqueia (BTEC), com o objetivo de observar a internalização dos exossomas por outras células e a promoção da comunicação celular. A análise da expressão dos genes *c-Myc* e *miR-21* demonstrou haver uma maior expressão nas células incubadas com exossomas derivados de células tumorais do que nas células controlo, sem exossomas, o que nos permite concluir que o *uptake* de exossomas e a transferência de informação ocorreu.

**Palavras-chave:** Exossomas, Cancro, Nanopartículas de ouro, Silenciamento génico, Comunicação celular



## ABSTRACT

Exosomes are small membrane vesicles secreted by most cell types, either normal or malignant and are found in most body fluids such as saliva, plasma and breast milk. In the past decade, the interest in these vesicles has been growing more and more since it was found that besides their beneficial functions such as the removal of cellular debris and unnecessary proteins during cell maturation process, they can also interact with other cells and transfer information between them, thus helping diseases like cancer to progress. The present work intended to use gold nanoparticles as vehicles for gene silencing in an attempt to reduce the tumor-derived exosome secretion, regulated by Rab27a protein, and also aimed to compare the exosome secretion between two breast cell lines, MCF7 and MDA. Changes in *RAB27A* gene expression were measured by Real-time Quantitative PCR and it was revealed a decreased in *RAB27A* gene expression, as expected. Exosomes were isolated and purified by two different methods, ultracentrifugation and the commercial kit ExoQuick™ Solution, and further characterized using Western Blot analysis. ExoQuick™ Solution was proven to be the most efficient method for exosome isolation and it was revealed that MDA cells secrete more exosomes. Furthermore, the isolated MCF7-derived exosomes were placed together with a normal bronchial/tracheal epithelial cell line (BTEC) for an additional assay, which aimed to observe the uptake of exosomes by other cells and the exosomes' capability of promoting cell-cell communication. This observation was made based on alterations in the expression levels of *c-Myc* and *miR-21* genes and the fact that they both have an increased expression in BTEC cells incubated with tumor-derived exosomes when compared to control cells (without incubation with the exosomes) lead us to the conclusion that the exosome uptake and exchange of information between the exosomes and the normal cells did occurred.

**Key words:** Exosomes, Cancer, Gold Nanoparticles, Gene Silencing, Cell-cell Communication



## TABLE OF CONTENTS

1	INTRODUCTION .....	1
1.1	CANCER.....	1
1.1.1	TUMORIGENESIS.....	1
1.1.1.1	MAIN CHARACTERISTICS OF CANCER .....	3
1.1.2	CANCER INCIDENCE AND MORTALITY .....	5
1.1.2.1	BREAST CANCER .....	6
1.1.3	CANCER THERAPY .....	7
1.1.3.1	NANOTECHNOLOGY FOR THERAPY .....	8
1.1.3.1.1	GOLD NANOPARTICLES .....	10
1.2	EXOSOMES.....	12
1.2.1	EXOSOMES IN CANCER AND HEALTH - BIMODAL ROLE OF EXOSOMES .....	12
1.2.2	BIOGENESIS AND RELEASE OF EXOSOMES .....	14
1.2.2.1	RAB27A.....	16
1.2.3	EXOSOMES COMPOSITION .....	17
1.2.4	UPTAKE OF EXOSOMES BY CELLS .....	19
1.2.5	EXOSOMES IN BREAST CANCER.....	21
1.3	SCOPE OF THE WORK .....	22
2	MATERIAL AND METHODS .....	23
2.1	CELL LINES.....	23
2.1.1	CELL LINE HANDLING AND MAINTENANCE .....	23
2.1.2	CELL VIABILITY MTS ASSAY .....	24
2.2	GOLD NANOPARTICLES.....	25
2.2.1	GOLD NANOPARTICLES SYNTHESIS .....	25
2.2.2	FUNCTIONALIZATION WITH POLYETHYLENE GLYCOL (PEG).....	26
2.2.3	AuNP@PEG FUNCTIONALIZATION WITH THIOLATED OLIGONUCLEOTIDES .....	26
2.2.4	QUANTIFICATION OF FUNCTIONALIZED OLIGONUCLEOTIDES ON AuNPs' SURFACE ...	27
2.3	GENE EXPRESSION EVALUATION ASSAY.....	27
2.3.1	RNA EXTRACTION .....	27
2.3.2	cDNA SYNTHESIS.....	28
2.3.3	cDNA AMPLIFICATION BY REAL QUANTITATIVE TIME PCR (qPCR).....	28
2.4	EXOSOME EXTRACTION AND PURIFICATION .....	30
2.5	QUANTIFICATION AND CHARACTERIZATION OF EXOSOMES – WESTERN BLOT.....	31

2.6	UPTAKE OF EXOSOMES BY NORMAL CELL LINES .....	32
2.6.1	EVALUATION OF <i>C-MYC</i> GENE EXPRESSION.....	32
2.6.1	<i>MIR-21</i> QUANTIFICATION.....	33
3	RESULTS AND DISCUSSION .....	35
3.1	SYNTHESIS AND CHARACTERIZATION OF GOLD NANOPARTICLES (AuNPs).....	35
3.2	RAB27A GENE SILENCING (IN MCF7 AND MDA) .....	36
3.3	EXOSOME QUANTIFICATION .....	39
3.3.1	COMPARISON BETWEEN ISOLATION METHODS – ULTRACENTRIFUGATION AND EXOQUICK™ SOLUTION .....	39
3.3.2	EXOSOME QUANTIFICATION IN MCF7 AND MDA CELLS.....	41
3.3.3	CHARACTERIZATION OF EXOSOMES - WESTERN BLOT .....	43
3.4	UPTAKE OF EXOSOMES BY NORMAL CELLS.....	45
3.4.1	<i>C-MYC</i> GENE EXPRESSION .....	45
3.4.2	<i>MIR-21</i> QUANTIFICATION.....	47
4	CONCLUSIONS AND FUTURE PERSPECTIVES .....	49
5	REFERENCES .....	51
6	APPENDICES.....	xxiii

## FIGURE INDEX

<b>Figure 1.1:</b> Illustration of the main capabilities acquired by cancer cells during tumorigenesis (Adapted from Hanahan and Weinberg, 2011). .....	2
<b>Figure 1.2:</b> Incidence and mortality rates of the most common cancers worldwide (Adapted from “GLOBOCAN,” 2012). .....	5
<b>Figure 1.3:</b> Breast cancer incidence and mortality rates in the United States (“Cancer of the breast - SEER Stat Fact Sheets,” 2012). .....	6
<b>Figure 1.4:</b> Schematic representation of gold nanoparticles functionalized with several biomolecules (Adapted from Conde et al., 2012). .....	9
<b>Figure 1.5:</b> Schematic representation of nanoparticles internalization and target mRNA with subsequent block of protein translation (Adapted from Zhang et al., 2014). .....	11
<b>Figure 1.6:</b> Schematic illustration of the exosomes’ biogenesis (Adapted from Bellingham et al., 2012). .....	15
<b>Figure 1.7:</b> Illustration of exosomes’ composition (Adapted from Bellingham et al., 2012). .....	18
<b>Figure 1.8:</b> Exosome uptake by recipient cells by a) receptors in the surface, b) fusion with the cell membrane or c) phagocytosis (Adapted from Kahlert and Kalluri, 2013). .....	20
<b>Figure 3.1:</b> Characterization of naked gold nanoparticles and functionalized with PEG (AuNP@PEG) and with PEG and antisense-Rab27a (AuNP@PEG@antisense-Rab27a) by A) UV/vis spectroscopy in the wavelength range of 400-800 nm (pH 7.0) with the absorbance peak at 518 nm; and B) DLS measurements with diameter distribution of naked AuNPs (blue), AuNP@PEG (red) and AuNP@PEG@antisense-Rab27a (green). .....	36
<b>Figure 3.2:</b> <i>RAB27A</i> gene expression evaluation in MCF7 cells incubated with AuNP@PEG and AuNP@PEG@antisense-Rab27a with concentrations of 20 nM and 30 nM. Gene expression variation is calculated through $2^{-\Delta\Delta C_t}$ , after normalization with <i>RNA18S</i> gene and control cells (exosome-depleted medium). The data are represented as means $\pm$ SEM of at least three independent experiments. .....	37
<b>Figure 3.3:</b> <i>RAB27A</i> gene expression evaluation in MCF7 cells (A) and MDA cells (B) incubated with AuNP@PEG and 20 nM of AuNP@PEG@antisense-Rab27a for 6 h and 12 h. Gene expression variation is calculated through $2^{-\Delta\Delta C_t}$ , after normalization with <i>RNA18S</i> gene and control cells (exosome-depleted medium). The data are represented as means $\pm$ SEM of at least three independent experiments. .....	38
<b>Figure 3.4:</b> Cell viability in MCF7 and MDA cells after incubation with AuNP@PEG and AuNP@PEG@antisense-Rab27a with exposure times of 6 h (A) and 12 h (B). Cell viability values were normalized in relation to the control group without exosomes. The data are represented as means $\pm$ SEM of at least two independent experiments. .....	39
<b>Figure 3.5:</b> Exosome quantification ( $\mu\text{g/mL}$ ) of both supernatant 1 and 2 after isolation by ultracentrifugation method, with and without sucrose gradient. The data are represented as means $\pm$ SEM of at least two independent experiments; * $p < 0.05$ as compared with ultracentrifugation with sucrose values. .....	40
<b>Figure 3.6:</b> Exosome quantification ( $\mu\text{g/mL}$ ) after isolation by ExoQuick™ Solution, with and without Amicon® Ultra-0.5 Filters. .....	41

**Figure 3.7:** Quantification of exosomes in MCF7 and MDA cells after isolation with ExoQuick™ Solution. The data are represented as means ± SEM of at least two independent experiments. .... 42

**Figure 3.8:** Quantification of exosomes in MCF7 and MDA cells when incubated with AuNP@PEG and AuNP@PEG@antisense-Rab27a. The data are represented as means ± SEM of at least two independent experiments; \*p < 0.005, as compared with the control group. The values were normalized in relation to the MCF and MDA control group without AuNP (only exosome-depleted medium). ..... 43

**Figure 3.9:** SDS-PAGE gel stained with Coomassie blue. Samples loaded into wells 1 and 2 correspond to exosomes lysates extracted from supernatants 1 and 2 by ultracentrifugation. Samples from the 3<sup>rd</sup> to the 6<sup>th</sup> well correspond to exosome lysates extracted from supernatants 1 and 2 by Exoquick Solution. .... 44

**Figure 3.10:** Western blot analysis of Alix protein in different amount of exosomes purified from supernatant 1 and 2 by ExoQuick Solution. Samples 1, 3 and 5 correspond to supernatant 1; samples 2, 4 and 6 correspond to supernatant 2. (M= molecular weight marker, NZYColour Protein Marker II). ..... 45

**Figure 3.11:** *c-Myc* gene expression evaluation in BTEC cells after incubation with 50 µg of MCF7-derived exosomes. Data was normalized relatively to *RNA18S* gene expression and subsequent normalization with BTEC cells that were not exposed to MCF7-derived exosomes. The data are represented as means ± SEM of at least two independent experiments. .... 46

**Figure 3.12:** Intracellular *c-Myc* gene expression in BTEC cells (A) and MCF7 cells (B). Data analyzed relatively to *RNA18S* gene expression. The data are represented as means ± SEM of at least two independent experiments; \*p < 0.005, as compared with *c-Myc* expression at 30 min. .... 47

**Figure 3.13:** *miR-21* expression variations in BTEC cells after incubation for 30 min and 2 h with 50 µg of MCF7-derived exosomes, with normalization to miRNA U6. Only one experiment was performed. .... 48

**Figure 3.14:** Cell viability in BTEC cell line incubated with 50 µg of tumor-derived exosomes. Cell viability values were normalized in relation to the control group without exosomes. The data are represented as means ± SEM of at least two independent experiments. .... 48

**Figure A.1:** Coverage of AuNP surface with PEG. A) Absorbance spectra of DTNB after reaction with PEG. B) Calibration curve for PEG chains. Concentration can be calculated with the equation  $Abs_{412\text{ nm}} = 921x + 9,0378$ , being  $x = [PEG, \text{mg/mL}]$ . C) Variation of PEG concentration incubated with AuNPs. It is shown that the 100% saturation point is obtained with 0.01mg/mL of PEG and above that no more PEG can bound to the AuNP's surface. .... xxiii

**Figure A.2:** Oligonucleotide quantification. Calibration curve obtained from fluorescence spectra. The amount of fluorophore-labelled oligonucleotides present in the supernatant can be determined using the following equation:  $Y = 6124,9x + 74,97$  ( $R^2 = 0,9904$ ). .... xxiv

**Figure A.3:** Characterization of gold nanoparticles by TEM. A) TEM images of naked AuNPs; B) TEM images of AuNP@PEG; C) Histogram with size distribution of naked AuNPs D) Histogram with size distribution of AuNP@PEG. .... xxv



## TABLE INDEX

<b>Table 2.1:</b> Concentrations used for cDNA template, primers forward and reverse and MgCl <sub>2</sub> for amplification by qPCR. ....	28
<b>Table 2.2:</b> Sequences of the primers used and expected amplification product size. ....	29
<b>Table 2.3:</b> qPCR cycling conditions. ....	29
<b>Table 2.4:</b> <i>c-Myc</i> primers' sequence and amplification product size. ....	33



## ABBREVIATION LIST

<b>A</b>	Adenin
<b>Abs</b>	Absorbance
<b>Abs<sub>260/230</sub></b>	Ratio between absorbance measured at 260nm and 230nm
<b>Abs<sub>260/280</sub></b>	Ratio between absorbance measured at 260nm and 280nm
<b>ACTB</b>	Gene that codes for $\beta$ -actin
<b>AuNP</b>	Gold nanoparticles
<b>BSA</b>	Bovine Serum Albumin
<b>BTEC</b>	Primary Bronchial/Tracheal Epithelial Normal Cells
<b>C</b>	Cytosine
<b>cDNA</b>	Complementar DNA
<b>CO<sub>2</sub></b>	Carbon dioxide
<b>Ct</b>	Cycle threshold
<b>DLS</b>	Dynamic Light Scattering
<b>DMEM</b>	Dulbecco's Modified Eagle Medium
<b>DNA</b>	Deoxyribonucleic Acid
<b>DNTB</b>	5,5'-dithio-bis(2-nitrobenzoic) acid
<b>DTT</b>	DL – Dithiothreitol
<b>ESCRT</b>	Endosomal Sorting Complexes Required for Transport
<b>Exo-FBS</b>	Exosome depleted Fetal Bovine Serum
<b>FBS</b>	Fetal Bovine Serum
<b>G</b>	Guanidine
<b>H<sub>2</sub>O</b>	Water
<b>HAuCl<sub>4</sub></b>	Chloroauric Acid
<b>HCl</b>	Chloridric Acid
<b>HNO<sub>3</sub></b>	Nitric Acid
<b>HRP</b>	Horseradish Peroxidase
<b>SPR</b>	Localized Surface Plasmon Resonance
<b>MCF7</b>	Human Breast Cancer Cell Line

<b>MDA-MB-453</b>	Human Breast Cancer Cell Line
<b>MgCl<sub>2</sub></b>	Magnesium Chloride
<b>mRNA</b>	Messenger RNA
<b>miRNA</b>	Micro Ribonucleic Acid
<b>MTS</b>	(3-(4,5-dimethylthiazol-2-yl)-5-(3-(carboxymethoxyphenyl)-2-(4-(sulfopheeryl)-2H-tetrazolium
<b>MVBs</b>	Multivesicular Bodies
<b>PEG</b>	Poly(ethylene glycol)
<b>PBS</b>	Phosphate Buffered Saline
<b>PCR</b>	Polymerase Chain Reaction
<b>PMSF</b>	Phenylmethylsulfonyl Fluoride
<b>qPCR</b>	Quantitative Polymerase Chain Reaction
<b>RNA</b>	Ribonucleic Acid
<b>SDS</b>	Sodium Dodecyl Sulfate
<b>SDS-PAGE</b>	Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis
<b>siRNA</b>	Small interfering RNA
<b>SPR</b>	Surface Plasmon Resonance
<b>T</b>	Thymine
<b>TAE</b>	Tris base, acetic acid and EDTA buffer
<b>TBST</b>	Tris-buffered saline with Tween 20
<b>TEM</b>	Transmission Electron Microscopy
<b>TEMED</b>	Tetramethylethylenediamine
<b>Tris-HCl</b>	Tris-Hydrochlorite
<b>UV</b>	Ultraviolet

#### **LIST OF UNITS**

<b>% (w/v)</b>	Weight/volume percentage
<b>% (v/v)</b>	Volume/volume percentage
<b>bp</b>	Base Pair
<b>°C</b>	Celsius degrees

<b>H; min; sec</b>	Hours; minutes; seconds
<b>Kg; g; mg; µg; ng</b>	Kilogram; Gram ( $10^{-3}$ kg); milligram ( $10^{-6}$ kg); microgram ( $10^{-9}$ kg); nanogram ( $10^{-12}$ kg)
<b>kDa</b>	Kilodalton
<b>L; mL; µL</b>	Liter; milliliter ( $10^{-3}$ L); microliter ( $10^{-6}$ L)
<b>M; cm; mm; nm</b>	Meter; centimeter ( $10^{-2}$ m); millimeter ( $10^{-3}$ m); nanometer ( $10^{-9}$ m)
<b>M; mM; µM; nM</b>	Molar (mol/L); milimolar ( $10^{-3}$ M); micromolar ( $10^{-6}$ M); nanomolar ( $10^{-9}$ M)
<b>mol; pmol</b>	Mole; picomol
<b>Rpm</b>	Rotations Per Minute
<b>V</b>	Volt

#### LIST OF SYMBOLS

<b><math>\epsilon</math></b>	Molar Extinction Coefficient
<b><math>l</math></b>	Optical Path
<b>%</b>	Percentage



# **1 INTRODUCTION**

## **1.1 CANCER**

Cancer consists in a highly complex disease that arises from the accumulation of several genetic events throughout life, in which cells undergo metabolic and behavioral changes, leading to uncontrolled proliferation which results in tumor production, invasion and metastasis (“World Cancer Report,” 2008; Zhang *et al.*, 2013). Under normal circumstances, growth is controlled by molecular mechanisms so that the rates of new cell growth and old cell death are kept in balance. Sometimes, this balance is no longer present because new cells grow too fast and old damaged cells do not die as they should and continue to proliferate, as a result of the accumulation of the genetic events. Over time, if not corrected, an organ can have the total number of cells altered and these aberrant cells can form an agglomerate so called tumor (Hanahan and Weinberg, 2011).

A person’s age, genetic, and lifestyle behaviors affect collectively the risk of developing cancer later in life. There are a number of phenomena, internal and external factors that can cause cancer, being only 5-10% of all cases due to genetic causes. Among internal factors we can find abnormal hormone levels, weakened immune system and hereditary factors that can predispose people to have certain types of cancer. In a major way, lifestyle (alcohol abuse, diet, tobacco) as well as exposure to environmental factors such as sunlight, exposure to chemicals, radiation and viruses can also contribute to cancer (Anand *et al.*, 2008; Nickels *et al.*, 2013).


### **1.1.1 TUMORIGENESIS**

Cancer development is a multi-step process as several things have to go wrong in order to a subset of cells gradually progress into a neoplastic state, where both genetic susceptibility and environmental changes together play important roles in the survival of abnormal cells (Herceg and Hainaut, 2007; “World Cancer Report,” 2008). The formation of a malignant tumor begins with genetic changes in somatic cells spontaneously or induced by exposure to an external factor, involving the deregulation of several genes such as proto-oncogenes, tumor suppressor genes or genes involved in cell cycle regulation and programmed cell death. When critical functions are altered cells should undergo a programmed form of cell death, as known as apoptosis. The critical point is when mutations occur in genes which control proliferation or apoptosis leading to cell survival and proliferation instead, causing an uncontrolled growth (Hanahan and Weinberg, 2011).

In our daily routine, DNA is continuously subjected to damage from exogenous agents that can be chemical (tobacco, diet, and alcohol), physical (ultraviolet and ionizing radiation) or biological (viruses) (Anand *et al.*, 2008). Chemical agents and ionizing radiation can attack DNA bases and

induce modifications in the coding sequence, for instance, ultraviolet irradiation is capable of disrupting the normal base pairing of DNA causing an obstacle for DNA polymerase (Ikehata and Ono, 2011). Likewise, lifestyle behaviors such as smoking, alcohol abuse as well as exposure to food additives and lack of fruit and vegetable intake have been linked to chronic inflammation which is believed to affect several stages in tumor development, immune surveillance and responses to therapy (Anand *et al.*, 2008; Grivennikov *et al.*, 2011). Viruses can also play an important role in human cancers, as for example the human papilloma virus (HPV) in cervix cancer (Schiller and Lowy, 2014). There are two types of viruses: DNA viruses which incorporate into the genome or RNA viruses, as known as retroviruses, which can transform the cellular genome thus leading to malignant changes (Devi, 2004; Schiller and Lowy, 2014). Spontaneous DNA mutations are frequent and there are errors that may occur and stay unrepaired, however, if those occur in essential genes involved in DNA repair and proliferation (*BRAC1*, *BRAC2*, *MSH2*, *MYH*), in regulatory genes (*RB1*), in genes associated with the apoptotic pathway (*BCL-2*) and in cycle checkpoint related genes (*TP53*), it becomes problematic (Bertram, 2001; Roma-Rodrigues *et al.*, 2014).

Tumors have a particular and complex microenvironment where hypoxia, acidic conditions and lack of nutrients prevail. To overcome this hostile environment tumor cells activate stress responses, inducing adaptive mechanisms in order to survive and only the fittest cells will thrive (Kucharzewska and Belting, 2013; Villarroya-Beltri *et al.*, 2014). In cancer's evolution, six major events must be achieved by the cell. It must be able to immortalize the replication processes and avoid apoptosis, trigger invasion and metastasis, promote angiogenesis, have self-proliferative signaling and must be capable to inhibit tumor growth suppressors (Figure 1.1) (Hanahan and Weinberg, 2011).



**Figure 1.1:** Illustration of the main capabilities acquired by cancer cells during tumorigenesis (Adapted from Hanahan and Weinberg, 2011).



### 1.1.1.1 MAIN CHARACTERISTICS OF CANCER

Cell cycle is a tightly regulated process in which cells must follow a number of rules and go through checkpoints that are mainly responsible for the evaluation of DNA integrity (Park and Lee, 2003). Cells only pass to a different cycle phase when they receive appropriate signals from a regulatory enzyme family called cyclin-dependent kinases (CDK); when DNA replication is not correct and cells are not able to repair it, a self-destruction processes (apoptosis) is activated to avoid errors' perpetuation; there is a limited number of times that a cell can divide itself due to telomeres that have a number of small repeats of DNA and when those end the cell cannot divide anymore. For a cell to turn malignant genes involved in cell cycle checkpoints may be mutated and all these rules are then broken. Cell division is permanently activated, defects in pathways involved in DNA damage response and DNA repair allow cells to avoid programmed cell death and so they divide and accumulate modifications over time (Hanahan and Weinberg, 2011; Park and Lee, 2003; "World Cancer Report," 2008). Also an enzyme called telomerase can be activated, allowing the addition of new repeats of DNA at the end of chromosomes which will compromise the genome integrity and give permission for cells to divide more than it is supposed to (Hanahan and Weinberg, 2011; "World Cancer Report," 2008).

Changes in genome can result from several events since genetic modifications, such as point mutations, mutations to stop codons, gene function deregulation and loss of a certain gene, to epigenetic modifications in DNA (Bertram, 2001; Hanahan and Weinberg, 2011; Herceg and Hainaut, 2007). Epigenetic is an expanding field defined as the study of "heritable changes in gene expression that are not due to any alteration in DNA sequence" (Esteller, 2008). DNA methylation and post-transcriptional modifications of histones (chromatin proteins) are two epigenetic mechanisms that may contribute to carcinogenesis (Esteller, 2008; Waldmann and Schneider, 2013). Acetylation, methylation, phosphorylation and ubiquitination of histones are modifications that have a profound effect on nuclear processes such as DNA repair, DNA replication and organization of chromosomes (Dawson and Kouzarides, 2012; Herceg and Hainaut, 2007). For instance, the addition of a methyl group to the 5-carbon position of cytosine bases located 5' to a guanosine base is a small modification of the DNA molecule that has important regulatory consequences. Two anomalous methylations are found in human cancer: hypomethylation, the loss of 5'-methyl-cytosine, associated with activation of proto-oncogenes as well as chromosome instability, and hypermethylation of the CpG islands in the promoter regions, linked to gene inactivation. There are a number of studies that point out hypermethylation has the cause of the silencing of tumor suppressor and other cancer-related genes (Dawson and Kouzarides, 2012; Waldmann and Schneider, 2013; "World Cancer Report," 2008). Oncogenes and suppressor genes are two classes of regulatory genes directly involved in tumor progression. When proto-oncogenes suffer an alteration and become constitutively activated they come to be called oncogenes and cells will grow with no control, since they are involved in stimulation of proliferation. Classic examples include *RAS* and *MYC* genes (Hanahan and Weinberg, 2011; Levine and Puzio-Kuter, 2010). *c-Myc* is the most investigated among *MYC* gene family because it is involved in several cellular processes such as replication, differentiation and apoptosis and it was

shown to be overexpressed in most types of human cancer (Miller *et al.*, 2013). In opposition to those, *TP53* and *PTEN* gene are examples of tumor suppressor genes which codes for proteins that usually regulate cell cycle and cell death in order to inhibit the tumorigenesis progression. Under-expression or loss of function will eventually lead to tumorigenesis (Hanahan and Weinberg, 2011; Levine and Puzio-Kuter, 2010).

The ability of tumor cells to detach from their place of origin to other organs is known as metastasis. This process involves several steps such as alterations in cell morphology, loss of cell adhesion to other cells and to the extracellular matrix (ECM), invasion of neighborhood tissues and blood circulation, migration, survival and colonization of other distant organs (Geiger and Peeper, 2009; Hanahan and Weinberg, 2011; Zhang *et al.*, 2013). A mechanism similar to Epithelial-Mesenchymal Transition (EMT) that happens during embryonic development and wound healing is required for an *in situ* carcinoma to become invasive and consists in the transformation of a number of epithelial cells into mesenchymal cells, thus being able to migrate (Hanahan and Weinberg, 2011; Zhang *et al.*, 2013). Epithelial cells are usually attached to each other and to ECM by adhesion and signaling molecules such as cadherins and integrins. E-cadherin helps in the formation of adherens junctions between adjacent epithelial cells and its downregulation is usually linked to the acquisition of the invasion and metastatic capability of cancer cells (Hanahan and Weinberg, 2011; Zhang *et al.*, 2013). In order to conclude the metastatic process, cancer cells have not only to disseminate through the body but also to be successful in the adaptation to other tissues' microenvironment (Hanahan and Weinberg, 2011). Given the difficulty to control the tumor spread, metastasis is believed to be the cause of 90% of human cancer deaths (Zhang *et al.*, 2013). Despite the poor prognostic, and because the well-known strategies to fight cancer like surgery or chemotherapy are not so effective in this cases, there are ongoing investigations to improve the treatment such as the use of growth factor inhibitors or monoclonal antibodies that target cancer cells, described below in chapter 1.1.3 (Geiger and Peeper, 2009; Hanahan and Weinberg, 2011; "World Cancer Report," 2008).

The nutrient supply and transport of malignant cells through blood and lymph vessels is only possible with the formation of tumor vascularization, being this process called angiogenesis (Katoch, 2013). Due to hypoxic conditions and lack of nutrients that tumors are exposed to, the creation of new capillaries and blood vessels is crucial for tumor survival although tumor vasculature is not an organized hierarchy, instead it is chaotic, leading to abnormal blood flow (Bergers and Benjamin, 2003; Geiger and Peeper, 2009). Generally, in processes such as wound healing and female reproductive cycle, there is a balance between anti-angiogenic (thrombospondin-1, angiostatin) and pro-angiogenic factors (Vascular endothelial growth factor A (VEGFA), epidermal growth factor (EGF)) but when there is an "angiogenic switch" this balance no longer exists falling to the pro-angiogenic side thus having an enhanced expression that will favor the tumor growth (Bergers and Benjamin, 2003; Geiger and Peeper, 2009).


As we can understand, normally cells are equipped with defense mechanisms that work with great efficacy at different levels until mutations occur and cells start to divide with no control, with the tendency for cellular repair mechanisms to be less effective as a person grows older. Urgent

prevention measures and treatment ways for these malignant alterations are necessary to overcome this disease that seems to be triggered by a multitude of factors over which people themselves can have no control.

**1.1.2 CANCER INCIDENCE AND MORTALITY**

Being an increasingly important subject, cancer has affected about 14 million people in 2012, worldwide and killed approximately 8.2 million, comparing to the 12.7 million cases and 7.1 million deaths in 2008 (“Global Cancer Society,” 2008, “WHO,” 2015). It is estimated that in the next two decades the number of cases will rise to about 70% (“WHO,” 2015).

Lung cancer, female breast cancer, colorectal and prostate cancer are the most common ones accounting for about 50% of all new cases each year (Figure 1.2) (“GLOBOCAN,” 2012). Incidence of kidney cancer, skin melanoma, oral or liver cancer has been increasing along the years due to their association to some lifestyle behaviors like higher alcohol consumption and exposure to excessive sunlight (Cancer Research UK, 2015).




**Figure 1.2:** Incidence and mortality rates of the most common cancers worldwide (Adapted from “GLOBOCAN,” 2012).

Exposure to specific carcinogens varies from a geographic location to another, being this proven by the different mutation patterns and variable incidence from each cancer type around the globe. For instance, the type and frequency of mutations in liver cancers differs between Europeans and Americans from African and Southern Asian people, due to a fungus that contaminates components of some foods in tropical areas. Another example is tobacco-related lung cancer which has greater incidence in economically-developed countries due to the earlier start in smoking consumption (“World Cancer Report,” 2008).

### 1.1.2.1 BREAST CANCER

Accounting for almost a third of all female cancer cases, breast cancer is the second most common cancer in developed regions, after lung cancer, and the most frequently found in women. In 2012, 1.67 million women were diagnosed with this type of cancer (“WHO,” 2015).

Both developed and underdeveloped countries have almost the same number of cases but the incidence rates can go from 27 cases per 100,000 people in Middle Africa and Eastern Asia to 96 per 100,000 in Western Europe, demonstrating once again the impact of environmental factors (“GLOBOCAN,” 2012). It is estimated that around 520,000 women died from breast cancer in 2012, with variable mortality rates around the world, about 130,000 of those corresponding to European women (Cancer Research UK, 2015). Luckily, it seems that people are more aware of this disease and so death rates of this type of cancer have been decreasing along the years, especially in women younger than 50 years old (Figure 1.3) (American Cancer Society, 2014). Fortunately, more than 90% of early-stage diagnosed women survive to breast cancer for at least five years in contrast to the 15% of those diagnosed in more advanced stages (Cancer Research UK, 2015; “WHO,” 2015).



**Figure 1.3:** Breast cancer incidence and mortality rates in the United States (“Cancer of the breast - SEER Stat Fact Sheets,” 2012).

### 1.1.3 CANCER THERAPY

Classical approaches for cancer treatment are surgery, radiotherapy and chemotherapy (Silva *et al.*, 2014). Surgical intervention has been a potent tool in the fight against cancer as it can be used for the removal of local tumor masses, treatment of pre-cancerous lesions and for removal of normal organs that have risk to develop cancer, like for example the removal of breasts and ovaries when mutations in *BRCA* genes are present, thus reducing the risk ("World Cancer Report," 2008). Radiotherapy is usually applied after surgery, depending on the tumor type, and it kills cancer cells mainly through necrosis, a form of cell death caused by external factors (Grivennikov *et al.*, 2011). In the presence of metastasis, surgical removal or local ablation by radiotherapy is not enough and so there is a need for systemic-based therapies. Cancer chemotherapy emerged around 1960 and is based on the intravenous administration of cytotoxic drugs in order to cope the cancer cells in the body (Crawford, 2013). Unfortunately cancer cells, contrary to normal cells, are exposed to an extensive genomic instability, thus being able to adapt to drugs by the activation of alternative pathways to overcome the inhibitory effect of the drug or enabling new genetic mutations, resulting in drug-resistant phenotypes (Mendelsohn, 2013). Drug toxicity, pharmacodynamics and pharmacokinetics have to be taken into account for an efficient treatment as well as drug concentration, however with the traditional chemotherapeutic agents there is a risk of DNA damage, superior to radiotherapy because they target cells that rapidly divide themselves and along with it some normal tissues too, causing toxic side effects in some patients (Bertram, 2001; Gerber, 2008; Mendelsohn, 2013). A better understanding of the mechanisms of cancer disease is leading to the finding of new approaches which are based on blocking cell proliferation or tumor vascularization, both processes presented in primary tumors and metastasis (Geiger and Peeper, 2009).

In the past decade, mechanism-based targeted therapies have become more important in the medical field so that specific mechanisms can be possible to inhibit, thus enabling treatments to have less nonspecific toxicity and fewer side effects (Gerber, 2008; Mendelsohn, 2013). The main goal is to inhibit the acquired capabilities of tumor growth and progression using anti-angiogenic and pro-apoptotic drugs, telomerase and cyclin-dependent kinase inhibitors, anti-inflammatory drugs, among others (Hanahan and Weinberg, 2011). Monoclonal antibodies to target molecules on the cell's surface began to be developed in the early 1980s and nowadays immunotherapy is used to inhibit growth factor receptors like, for example, EGFR (a tyrosine kinase also known as HER1) required for tumor growth and also metastasis (Gerber, 2008; Mendelsohn, 2013). Clinical trials for personalized cancer vaccines are progressing in a very promising way although problems like costs and effort in their creation may be in the way and hamper the overall process (Cross and Burmester, 2006). Since angiogenesis influences cell proliferation and survival too, one has to think that targeting of angiogenic pathways is another anticancer approach, and being VEGF a pro-angiogenic factor, most research has focused on inhibiting its action with tyrosine kinase inhibitors or antibodies against VEGF receptors (Geiger and Peeper, 2009; Katoh, 2013). Although it is often used in association with

chemotherapy, targeted therapy has improved the life and prognostics of several cancer patients that would not otherwise live long enough (Gerber, 2008).


Developing new targeted therapies is expensive and not everyone can afford the existing treatments (Mendelsohn, 2013). However, global battle against cancer will not be won with only treatment, it is imperative to have prevention measures against cancer – reduce or eliminate the exposure to cancer-causing factors (tobacco, low physic activity, low nutrient intake...) and also to be aware of the symptoms so that early-stage diagnosis can be possible. With these preventing actions, along with the promising therapies, it is reasonable to think that it is possible for us to overcome someday this powerful disease that still takes away so many lives.

### 1.1.3.1 NANOTECHNOLOGY FOR THERAPY

Most cancer therapies have too many side effects and are not efficient due to drug resistance acquired by cancer cells and the inability to reach the target site in adequate concentrations (Mendelsohn, 2013). In an attempt to overcome these problems, nanotechnology has been the center of much attention in the past decade since it holds great promise in the improvement of targeted therapies (Azmi *et al.*, 2013; Sanvicens and Marco, 2008). The development of nanodevices for cancer therapies aims to target the delivery of drugs to cancer cells and enhance the possibility of early diagnostic or prevention with reduced toxicity and immune system responses avoidance (Heath and Davis, 2008; Sanz *et al.*, 2012) There exists a large variety of delivery systems including polymeric nanoparticles, liposomes, dendrimers, micelles, carbon nanotubes, quantum dots and inorganic nanoparticles (gold and silver nanoparticles for example), among others, which allow the use of nanoparticles in several applications, depending on their shape, size and purpose (Martins *et al.*, 2014; Silva *et al.*, 2014; Sperling and Parak, 2010).

Metal nanoparticles (NPs), especially gold nanoparticles (AuNPs), possess unique properties, both physical and chemical, that turns them into powerful tool for imaging, diagnosis and therapy, with less side effects (Conde *et al.*, 2010; Martins *et al.*, 2014). The fact that they can be modulated in shape, size, composition and other characteristics and have a size ranging 1-100 nm, similar to several biomolecules such as nucleic acids and antibodies, together with their high surface:volume ratio and the possibility of engineering their surface as desired, *i.e.*, can be functionalized with biomolecules (Figure 1.4), potentiate nanoparticles to be directed to specific cells and have different circulation times in the organism (Conde *et al.*, 2012b; Sanvicens and Marco, 2008; Silva *et al.*, 2014). Because nanometer-size particles are sufficiently large to contain multiple targeting ligands and a variety of drug molecules as well as the fact that they can bypass multidrug resistance mechanisms, it is possible to create new strategies for therapy (Heath and Davis, 2008; Martins *et al.*, 2014). Controlling the size of the nanoparticles is important because it will influence optical and electric properties, the pharmacokinetics, biodistribution and accumulation in tumor site. Nanoparticles should not be smaller than 10 nm in order to avoid renal clearance and the surface charge must be neutral or

negative so it can be possible to minimize nonspecific interactions with other molecules and avoid immune reactions (Heath and Davis, 2008; Sanz *et al.*, 2012). The nanodevices can reach the tumor by passive or active targeting. Passive target is based on the delivery systems properties in order to accumulate the drug in the target site and avoid a non-specific distribution (Ganta *et al.*, 2008; Martins *et al.*, 2014). Due to the abnormal tumor vascularization, there is an enhanced permeability and retention (EPR) conferring to nanoparticles the ability to accumulate in tumors and it is also possible by functionalization with hydrophilic molecules such as poly(ethylene glycol) (PEG) that increases their solubility (Conde *et al.*, 2012b; Silva *et al.*, 2014). Active target, on the other hand, depends on the functionalization of the nanoparticle with a specific ligand, such as an antibody, protein or DNA/RNA, thus enabling to cross tumor cells, providing a more effective targeting (Conde *et al.*, 2012b; Ganta *et al.*, 2008; Martins *et al.*, 2014).



**Figure 1.4:** Schematic representation of gold nanoparticles functionalized with several biomolecules (Adapted from Conde *et al.*, 2012).

The application of nanoparticles in medicine requires stability in solutions with high protein and salt concentrations (Liu *et al.*, 2007). In order to achieve such stability, ligand molecules such as thiol groups are bound to the NP surface, controlling the growth during synthesis and preventing the aggregation between particles due to repulsive forces (Sperling and Parak, 2010). Surface modification with thiolated poly(ethylene glycol) has been demonstrated to increase the particles' circulation time once it allows to avoid the uptake by immune system cells and provide stability to NP

in biological environments because it prevents non-specific binding of proteins and cells due to steric effects (Alexis *et al.*, 2010; Sanz *et al.*, 2012).

Despite the recognized advantages that nanoparticles bring to medicine, some challenges remain to overcome (Martins *et al.*, 2014; Sanvicens and Marco, 2008). There are toxicological and ethical concerns that may postpone the regular clinical use of this emerging field, as well as the need for further optimization and fully understand of their potential and mechanisms of action (Sanvicens and Marco, 2008; Silva *et al.*, 2014).


#### **1.1.3.1.1 GOLD NANOPARTICLES**

Easily synthesized, with a reduction method by citrate (Turkevich *et al.*, 1951), gold nanoparticles combined with biomolecules have been widely studied, with great potential for medical therapies, and several methods have been developed to characterize them, centered on their physico-chemical properties, such as the localized surface plasmon resonance (LSPR) (Baptista, 2012).

UV/visible spectroscopy is the most used method for characterizing the nanoparticles based on their optical properties and electronic structure since the absorption bands are related to their size (Philip, 2008). LSPR is described as the oscillation of the free electrons across the nanoparticle, induced by an electromagnetic field, resulting in an enhancement of absorption and scattering of the electromagnetic radiation, thus giving an intense color and other optical properties to the nanoparticles (Jain *et al.*, 2007). The SPR is a consequence of their small size and is dependent on several properties such as metal composition, shape and surface functionalization of the nanoparticles as well as dielectric properties of the surrounding medium (Jain *et al.*, 2007; Philip, 2008). A colloidal solution of Au nanospheres with a diameter around 20 nm has an intense ultraviolet-visible light extinction band at 520 nm, which gives them their characteristic red color. Increasing the diameter will shift the SPR band to higher wavelengths, changing their color, and the same happens when the refractive index of the surrounding environment increases due to a change in shape or nanoparticles aggregate, for instance (Alkilany and Murphy, 2010; Baptista, 2012). Supporting UV/visible spectroscopy, the characterization of AuNPs can also be done by Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM) (Liu *et al.*, 2007; Sanz *et al.*, 2012). While TEM analysis gives the real radius of the nanoparticles and permits to see the structure and determine the average size, DLS gives the hydrodynamic radius and allows us to confirm the functionalization efficacy with biomolecules by the increased radius of the nanoparticle when functionalized, compared to a non-functionalized nanoparticle (Liu *et al.*, 2007). The hydrodynamic radius can be calculated by exposure of a colloidal solution, with nanospheres in a Brownian motion, to a light beam, such as a laser. When the light hits the moving particles, the direction and intensity of the light are altered with the size of the particle, due to scattering, and it is dependent on features such as viscosity and temperature of the surrounding medium (Lim *et al.*, 2013).



Strategies for targeted therapy based on gold nanoparticles have been proposed due to their properties previously mentioned as well as the lack of toxicity to cells (Conde *et al.*, 2014). Usually cells resist to the uptake of genetic material and have mechanisms to degrade nucleic acids but since AuNPs can be functionalized with biomolecules and have been considered good vehicles for therapy once they protect against degradation by nucleases, producing nanoparticles with thiol-modified oligonucleotides in their surface is a good approach for specific gene regulation (Doria *et al.*, 2010; Patel *et al.*, 2008). Antisense oligonucleotides are DNA fragments capable of bind to its complementary mRNA, and can be in a hairpin structure, which only opens and hybridizes when it finds the complementary target sequence (Fichou and Fe, 2006; Rosa *et al.*, 2012). Gene expression inhibition is post-transcriptional thus preventing the translation of the mRNA into a protein (Figure 1.5), by either cleavage of the mRNA-oligonucleotide heteroduplex by RNase H or by steric blockage of the ribosomal machinery (Conde *et al.*, 2010; Fichou and Fe, 2006). The ability that lower amounts of AuNPs have to inhibit gene expression at the same levels of therapies with free oligonucleotides demonstrates the great efficiency of these particles in a simple, inexpensive and direct method (Baptista *et al.*, 2013).



**Figure 1.5:** Schematic representation of nanoparticles internalization and target mRNA with subsequent block of protein translation (Adapted from Zhang *et al.*, 2014).

## 1.2 EXOSOMES

Exosomes are small membrane vesicles (30-100 nm in diameter) of endocytic origin, first described as membrane fragments isolated from biological fluids by Trams and collaborators in 1981 and with greater relevance achieved after Johnstone and colleagues studied them a few years later (Johnstone *et al.*, 1987; Trams *et al.*, 1981; Zhang and Grizzle, 2014). Exosomes were initially thought to be organelles involved in the removal of cellular debris but now it is known that they play an important role in several processes like immunological processes, cell-cell communication and diagnostics, becoming a subject of interest in various research fields over the past decade (Bang and Thum, 2012; Zhang and Grizzle, 2014).

Cells are known to communicate and exchange information by direct contact, secretion of soluble factors or by secreting a large variety of vesicles into the extracellular space (El Andaloussi *et al.*, 2013). One can distinguish exosomes from apoptotic bodies and regular microvesicles. Microvesicles are released into the extracellular space by outward budding of plasma membrane in response to calcium influx, are heterogeneous in shape and size (100-1000 nm) whereas exosomes are formed by invagination of plasma membrane with endosomes followed by their release in the extracellular space and its shape is more uniform. Also it was shown that microvesicles sediment at a lower sucrose gradient than exosomes and their protein composition is different too. These two classes are distinct from apoptotic bodies which are released from cells that are passing through apoptosis or mechanical stress, thus being larger (0.5 – 3  $\mu\text{m}$ ) and with different molecular composition (Akers *et al.*, 2013; Kharaziha *et al.*, 2012; Muralidharan-Chari *et al.*, 2010).

Exosomes are secreted by most cell types, both normal and malignant and are found in most body fluids such as urine, saliva, plasma, amniotic liquid, breast milk, diseased fluids (i.e. pleural effusions for example), among others, implying that they play a role in both normal and pathological conditions (Braicu *et al.*, 2015; Record *et al.*, 2011; Zhang and Grizzle, 2014).

### 1.2.1 EXOSOMES IN CANCER AND HEALTH - BIMODAL ROLE OF EXOSOMES

Besides their function in the removal of unnecessary proteins during the cell maturation process (Vlassov *et al.*, 2012), once released into the extracellular space, exosomes are able to interact with cells in the neighborhood or to course long distances enabling the transfer of biomolecules like proteins, lipids and RNA between different cells by cell surface interactions, modulating their phenotypes (Kahlert and Kalluri, 2013; Roma-Rodrigues *et al.*, 2014). This modulation of the cells' phenotype is dependent on the origin of the exosomes: positive effects are triggered by exosomes released from normal cells whereas those from tumor or infected cells may cause non-positive health effects by the transfer of oncogenic features (Record *et al.*, 2011). It has been demonstrated that cancer patients have an increased content of these vesicles in their biological fluids when compared to healthy patients and as the tumor progresses its content increases even more (Bang and Thum, 2012;

Riches *et al.*, 2014). Situations of stress like exposure to hypoxia, starvation or acidic conditions are common in tumor microenvironment and, as previously explained in section 1.1.1.1, cancer cells need to overcome it so the tumor can progress (Villarroya-Beltri *et al.*, 2014). For that to happen, these stress conditions promote the release and trafficking of tumor-related exosomes that may contribute to tumor growth and evasion since they can alter the surrounding microenvironment through secretion of matrix metalloproteinases (MMPs) or its activators, such as heat shock proteins (HSPs), which degrade proteins from the extracellular matrix such as collagen and fibronectin, thus enabling cells to migrate (Hannafon and Ding, 2013; Muralidharan-Chari *et al.*, 2010). Also, these little vesicles can stimulate angiogenesis by inducing the expression of VEGF and cytokines and can also escape from immune surveillance and trigger an immunosuppressive response, and thus propagate oncogenic information through the organism, allowing tumor dissemination (Record *et al.*, 2011; Villarroya-Beltri *et al.*, 2014; Zhang and Grizzle, 2014).

Multidrug resistance (MDR) is believed to be one of the major problems of cancer therapy because drugs are expelled to the extracellular space by ABC transporters (ATP binding-cassette transporters) thus losing its effect on cancer cells. Since exosomes carry ABC transporters, it was thought that the mechanism of drug expulsion by cells can be mediated by these vesicles (Azmi *et al.*, 2013). There has also been several studies that indicate an association between exosomes and infection, cardiovascular diseases and neurodegenerative diseases (Bellingham *et al.*, 2012; Roma-Rodrigues *et al.*, 2014). Retroviruses and exosomes have been compared due to their resemblance in composition and mechanism of action and it was demonstrated that exosomes have the capability of spread pathogens such as prions and viruses, like HIV virus for example (Tan *et al.*, 2013; Vlassov *et al.*, 2012). When infected, cells from the immune system, like dendritic cells and macrophages, can produce and release exosomes as well as HIV virions since macrophages can fuse with late endosomes and then release their infectious content in the extracellular space, similar to what happens in exosomes' biogenesis (Johnstone, 2006; Record *et al.*, 2011). The fact that HIV and exosomes share propagation mechanisms, similar size and 10% of protein content might be the basis of the explanation of how this type of virus have the ability, like exosomes, of crossing the blood-brain barrier (El Andaloussi *et al.*, 2013; Record *et al.*, 2011).

Easily obtained from biological fluids in a non-invasive manner, found in unexpected numbers ( $\approx 10^{10}$ /mL) in the plasma of healthy individuals and with characteristics of the cell of origin, exosomes can, on the other hand, be beneficial for us (Kahlert and Kalluri, 2013; Yellon and Davidson, 2014). Mast cells, dendritic cells, macrophages and other types of cells involved in the immune system use exosomes to communicate and perform their normal functions and because exosomes are secreted by those and by stem cells too, they are capable of elicit an anti-tumor response by transporting tumor antigens to dendritic cells inducing an immune response and they can also participate in tissue repair (Bang and Thum, 2012; Zhang and Grizzle, 2014). Expressing in their surface Fas ligand, an immunosuppressive and anti-inflammatory molecule, in order to reduce the immune capacity during pregnancy is another example of exosome's role in the immune system and there are also evidences that they are involved in cell-cell communication during atherosclerosis protection, in the regulation of

neuronal cell function and that those secreted by mesenchymal stem cells possesses cytoprotective properties (El Andaloussi *et al.*, 2013; Roma-Rodrigues *et al.*, 2014; Zhang and Grizzle, 2014).

Because of their role in immune responses, exosomes-based vaccines have been proposed for clinical immunotherapy and other exosome-based therapies have been thought as strategies against cancer and other diseases (Roma-Rodrigues *et al.*, 2014; Théry *et al.*, 2002). Engineering exosomes to carry drugs or target proteins is one of the future strategies as well as nanobased formulations to mimic exosomes (Azmi *et al.*, 2013). Exosome research has been benefited by nanosystems, which have already helped in detection and characterization as well as in loading exosomes for further use in immunotherapy for instance (Azmi *et al.*, 2013). Once natural transporters, they can be modified to express certain proteins in their surface in order to be a potential novel targeted-therapy strategy with less or none toxicity or immune responses associated (Bang and Thum, 2012), supporting the possibility of using exosomes as therapeutic tool for drug delivery. There are some studies already made on mice showing that dendritic-derived exosomes with interference RNA (RNAi) were able to be delivered in the brain with no immune response associated and the inactivation of a neuron protein responsible for the formation of beta-amyloid plaques in Alzheimer's disease was possible with exosomes transporting siRNA molecules (Azmi *et al.*, 2013; Bang and Thum, 2012). Furthermore, exosomes are able to provide paramount information about the tumor biology owing to their specific protein content and because their concentration in a patient's body has been demonstrated to be in correlation with the state of the disease, they can be used in diagnostics as biomarkers to predict how cancer will develop and how it should be treated in a personalized way (Kahlert and Kalluri, 2013; Vaiselbuh, 2015).


Therefore, the question now is how important is their influence? The circulating exosomes have been implicated in cancer and other diseases but is that their main biological role? Sure they can promote harm but they are also implicated in the transfer of biomolecules between cells which might represent a new paradigm of intracellular information transmission, as well as a new form of therapy for several diseases. This being said, and despite the progresses that have already been made, there is still a long road ahead and much more to explore about exosomes and their bimodal role in our complex organism and the interest on them will grow more and more in the future.

### **1.2.2 BIOGENESIS AND RELEASE OF EXOSOMES**

Exosomes biogenesis is a highly regulated and unidirectional process performed within the endosomal system, which comprises early endosomes (EE), multivesicular bodies (MVBs), also known as late endosomes, and lysosomes (Bellingham *et al.*, 2012; Denzer *et al.*, 2000). This endocytic pathway is essential to homeostasis because it controls a variety of activities in every cell such as internalization and degradation of macromolecules, plasma membrane composition, signal transmission, nutrient uptake and defense against invading microorganisms (Fader and Colombo, 2009; Mellman, 1996). The membrane trafficking pathway is based on the internalization of

macromolecules, lipids or proteins by the plasma membrane which outgrows inside the cell and forms a vesicle containing the material which then fuses with early endosome, with a slightly acidic lumen, located at the periphery of the cell. Molecules inside early endosomes can then be recycled to the plasma membrane or transported to lysosomes for degradation. If the latter, molecules are sent to late endosomes in a transport mediated by carrier vesicles along microtubules. Late endosomes then mature into lysosomes and their environment becomes more acidic, allowing the degradation of the inner material by acidic hydrolases then staying as resting lysosomes until being activated again by the fusion with another late endosome (Grant and Donaldson, 2011; Mellman, 1996). Classic endocytic mechanisms include clathrin-dependent endocytosis, pinocytosis and phagocytosis (Svensson *et al.*, 2013). Families of small G proteins (Arf, Rab and Rho GTPases) have a very important role in endocytosis, each one interacting with effector proteins of the endocytic pathway and regulating different mechanisms in trafficking process such as vesicle movement and fusion with target membranes (Doherty and McMahon, 2009; Grant and Donaldson, 2011).

Genesis of exosomes through multivesicular bodies was first referred by Johnstone and collaborators (Johnstone *et al.*, 1987). Depending on their biochemical properties, MVBs can either fuse with lysosomes, resulting in the degradation of proteins and lipids or they can fuse with the plasma membrane leading to the release of internal vesicles (ILVs) into the extracellular space, where they are then referred to as exosomes (Figure 1.6) (Keller *et al.*, 2006; Mathivanan *et al.*, 2010). How vesicles go either destination is not completely understood however exosome secretion is a regulated process, believed to be coordinated by several molecules promoted by different stimuli, either mechanical, chemical or biological such as low oxygen, low pH, gamma-irradiation, among others (Bang and Thum, 2012; Hannafon and Ding, 2013; Kharaziha *et al.*, 2012). Fusion of MVBs with the plasma membrane and consequent release can either be spontaneous, via Trans-Golgi Network, or induced by a cell surface receptor, depending on the cell type and its activation state (Kucharzewska and Belting, 2013; Record *et al.*, 2014).



**Figure 1.6:** Schematic illustration of the exosomes' biogenesis (Adapted from Bellingham *et al.*, 2012).

Biogenesis of MVBs comprises the formation of membrane buds, sorting of ubiquitinated cargo and cleavage of those buds, which will originate the ILVs (Hurley and Hanson, 2010). A complex named ESCRT (Endosomal Sorting Complex Required for Transport), which recognizes ubiquitinated proteins, is required for MVBs and ILVs' formation and recruitment of proteins to exosomes (Hurley and Hanson, 2010; Kahlert and Kalluri, 2013). ESCRT machinery is composed by four complexes, ESCRT-0, ESCRT-I, ESCRT-II and ESCRT-III which are associated with Alix and Tsg101 proteins, also presented in exosomes (Raposo and Stoorvogel, 2013; Record *et al.*, 2011; Villarroya-Beltri *et al.*, 2014). The recognition of ubiquitinated proteins in the endosomal membrane is made by ESCRT-0, -I and -II whereas ESCRT-III, recruited by the previous complexes, is responsible for membrane budding and ILVs' release (Hannafon and Ding, 2013; Hurley and Hanson, 2010). However, there are other pathways for these processes of MVB formation and exosomes' secretion (Soekmadji *et al.*, 2013; van der Pol *et al.*, 2012). After being observed that cells with depletion of the ESCRT subunits still secrete exosomes, it was demonstrated that an ESCRT-independent mechanism can also be involved in exosome formation and release, dependent on sphingomyelinase, an enzyme that produces ceramide from sphingomyelin, thus triggering the inward budding of exosomes in the MVB' membrane, allowing vesicle secretion (Kahlert and Kalluri, 2013; Raposo and Stoorvogel, 2013). Increases in intracellular calcium and depolarization induced by potassium appears to lead to the release of a superior amount of exosomes (Kahlert and Kalluri, 2013; Record *et al.*, 2014) and also other molecules of the endocytic pathway have been implicated in this process such as cytoskeleton regulatory pathways, heparanase, Rab GTPases and SNARES (Soluble NSF Attachment Protein Receptor), as well as proteins such as p53 and Alix (Bang and Thum, 2012; Kucharzewska and Belting, 2013; Roma-Rodrigues *et al.*, 2014). It was observed that, in cells undergoing stress conditions, occurred an activation of the tumor suppressor activated pathway-6 (TSAP6) by the tumor suppressor protein p53 and it was found that over-expression of the same pathway upregulates exosome secretion, similar to what happens with constitutively active or over-expressed Rab GTPases, common in cancer (Henderson and Azorsa, 2012; Record *et al.*, 2011).

#### **1.2.2.1 RAB27A**

The Rab small GTP-binding protein family is believed to be responsible for the coordination of several steps in vesicle trafficking, with over 60 Rab proteins identified in humans (Fukuda, 2013; Grant and Donaldson, 2011). These proteins switch between a GDP-bound "off" state and a GTP-bound "on" state, an inactive and active form respectively, controlled by two regulatory enzymes, guanine nucleotide exchange factor (GEF, activator) and a GTPase-activating protein (GAP, inactivator) and have different positions and functions in the process, including budding, mobility, docking and fusion (Fukuda, 2013; Grant and Donaldson, 2011). Rab GTPases are ubiquitously expressed in a considerable amount of secretory cells including exocrine, endocrine, ovarian and hematopoietic cells and their roles could depend on the cell type, be complementary or indirect by


regulating pathways upstream of exosome secretion (Hannafon and Ding, 2013; Raposo and Stoorvogel, 2013; Wang *et al.*, 2008).

Rab27a has been associated with the regulation of exosomes' secretion pathway by promoting the displacement of MVBs to the cell periphery and subsequent docking at the plasma membrane (Hannafon and Ding, 2013; Ostrowski *et al.*, 2010; Raposo and Stoorvogel, 2013). Ostrowski and colleagues demonstrated that the knockdown of Rab27a and its effector Slp4 (Synaptotagmin-like protein) inhibit the exosome secretion in HeLa cells, by either increasing the size of MVBs, which impossibilities the docking of those to the plasma membrane or Rab27a is required for docking and, when absent, vesicles will fuse with each other instead of fusion with the plasma membrane (Kharaziha *et al.*, 2012; Ostrowski *et al.*, 2010). The secretion of exosomes can be promoted by hypoxia and the inhibition of Rab27a has been associated with reduced mobilization of neutrophils, which leads to decreased tumor growth and lung metastasis, demonstrating that Rab27a is involved in cancer progression (Azmi *et al.*, 2013; Kahlert and Kalluri, 2013). Overexpression of Rab27a has been associated with the invasive and metastatic potential of human breast cancer cells by promoting the secretion of insulin-like growth factor II (IGF-II), involved in several roles in normal and breast cancer cells such as regulation of VEGF (Hendrix and de Wever, 2013; Wang *et al.*, 2008).

### **1.2.3 EXOSOMES COMPOSITION**

From exosome isolation by centrifugation or a protein-selective method, much can be discover about exosomes' composition (Johnstone, 2006). In order to study the exosomes, currently there are many methods that enable us to isolate and characterize them based on their size, density (1.13-1.19 g/mL) or specific marker proteins, from a variety of pathological and healthy fluids (Kharaziha *et al.*, 2012; Théry *et al.*, 2006). The isolation of exosomes from the supernatants of cultured cells is commonly performed by serial centrifugations (to first remove cells and cellular debris) and a ultracentrifugation (to pellet the exosomes) which can be combined with sucrose gradients for further purification since exosomes have a distinct density floatation from other classes of vesicles and because this method often brings impurities from other vesicles or cellular debris (Théry *et al.*, 2006; Vlassov *et al.*, 2012). Other methods that allow us to obtain exosomes include immunoprecipitation using magnetic beads with monoclonal antibodies specific for exosome antigens, even though it is necessary a good knowledge of the vesicles in study, and size-exclusion chromatography, besides other commercially available kits that already exists and provide a faster process for exosome isolation (Bobrie *et al.*, 2012; Soekmadji *et al.*, 2013; Tran *et al.*, 2015). Furthermore, exosomes can be characterized by western blot analysis, flow cytometry, LC-MS/MS or image techniques such as transmission electron microscopy and fluorescence microscopy, which allow a more accurate identification of these vesicles based on morphological and biochemical characteristics (Koga *et al.*, 2005; Mathivanan *et al.*, 2010; Muller *et al.*, 2014; Valadi *et al.*, 2007).

According to the latest version of ExoCarta Database, exosomes are very complex, with about 9000 proteins already recognized in different cell types and organisms, which allow us to identify and differentiate them from other vesicles (Bang and Thum, 2012; “ExoCarta,” 2015). Due to their endosomal origin, proteomic analysis from different cell lines and biological fluids indicate that exosomes are composed by proteins involved in membrane transport and fusion such as actin, annexin and Rab proteins, heat-shock proteins (Hsp70, Hsp90), tetraspanins (CD9, CD63, CD81, CD82) and also proteins involved in the biogenesis of MVBs like Alix and Tsg101, as illustrated in Figure 1.7 (Record *et al.*, 2011; Villarroya-Beltri *et al.*, 2014; Vlassov *et al.*, 2012). Besides those marker proteins, they also carry nucleic acids such as DNA, mitochondrial DNA (mtDNA), mRNA, microRNAs (miRNAs) and other non-coding RNAs (ncRNAs), ribosomal RNAs (rRNAs), transfer RNAs (tRNAs) (Roma-Rodrigues *et al.*, 2014; Vaiselbuh, 2015; Zhang *et al.*, 2015) and have a lipid bilayer composed by phospholipids, cholesterol, ceramide and sphingolipids, which stiffens the vesicle membrane thus conferring to the exosomes greater stability within the environment they are found (Roma-Rodrigues *et al.*, 2014; Villarroya-Beltri *et al.*, 2014; Vlassov *et al.*, 2012). Exosomes also contain proteins involved in signaling pathways such as  $\beta$ -catenin and Wnt5B and mediators of cell signaling like interleukin-1 $\beta$  and TNF- $\alpha$  (Urbanelli *et al.*, 2013). The specific composition depends on the cell type or tissue of origin and may differ according to physiological conditions (Hannafon and Ding, 2013). For instance, exosomes derived from antigen-presenting cells have in their surface the major histocompatibility complex (MHC) I and II whereas exosomes derived from oligodendrocytes contain myelin proteins (Soekmadji *et al.*, 2013; Tran *et al.*, 2015).



**Figure 1.7:** Illustration of exosomes' composition (Adapted from Bellingham *et al.*, 2012).




MicroRNAs are a class of small non-coding RNAs (17-24 nucleotides) implicated in post-transcriptional modifications of gene expression observed within a cell or in adjacent cells, thus showing that they circulate throughout the organism (Azmi *et al.*, 2013; Zhang *et al.*, 2015). Recent studies have demonstrated that this circulation can be exosome-mediated and could be a mechanism of genetic information exchange between cells (Valadi *et al.*, 2007; Zhang *et al.*, 2015). By being transported inside exosomes, RNAs are protected from degradation by RNase enzymes and the fusion of exosomes with a target cell membrane in the neighborhood or in a distant place allows the transfer of microRNAs between cells, which can lead to mRNA degradation or de-stabilization in the recipient cell, depending on the degree of complementarity between them both, eventually resulting in gene knockout (Gajos-Michniewicz *et al.*, 2014; Henderson and Azorsa, 2012). miRNAs are presented in body fluids and have been related to several processes including cell proliferation, cell differentiation and migration as well as disease initiation and progression, being their expression altered under pathological conditions (Zhang *et al.*, 2015). For instance, miR-21 and miR-141 had a lower expression level in exosomes from healthy patients than those from patients with malignant tumors (Zhang *et al.*, 2015). Studies shown that these molecules can have tumor suppressor or oncogenic activities such as miRNA let-7, which regulates cell proliferation and is found with low expression levels in cancers, in opposition to miR-21, which acts as an oncogene, silencing an antiapoptotic gene, thus contributing to cell survival (Gajos-Michniewicz *et al.*, 2014; Henderson and Azorsa, 2012). The transfer of exosome-secreted miRNAs can enhance the invasive potential of cancer cell lines, as well as promote interactions between different cell types and also confer pro-angiogenic properties (Azmi *et al.*, 2013).

Although a lot of research is still necessary, it is believed that exosomal miRNAs are characteristic of the cell from which exosomes were originated and therefore, miRNAs profiles in exosomes released from pathological or cancer cell might serve as biomarkers for several diseases (Gajos-Michniewicz *et al.*, 2014). The intriguing fact that exosomes contain RNA that can be delivered in recipient cells and have an active role on those, either by translation into proteins in the case of mRNA or repression of gene expression in the case of miRNA might become an ideal pathway to provide a new targeted-therapy strategy (Braicu *et al.*, 2015).

#### **1.2.4 UPTAKE OF EXOSOMES BY CELLS**

When released, exosomes can stay in circulation and travel through body fluids or alternatively they can be internalized by near or distant cells, transferring material between cells (Record *et al.*, 2014). Several mechanisms have been discussed to describe how exosomes are internalized in other cells and exchange information and, even though it still is a poorly understood subject, it is thought to be dependent on the type and the phagocytic capabilities of the target cell (Record *et al.*, 2011; Valadi *et al.*, 2007).

Exosomes can interact with the recipient cell by three main mechanisms: contact by receptors in the plasma membrane of the cell, fusion with the membrane of the target cell or by endocytosis, as illustrated in Figure 1.8 (Kahlert and Kalluri, 2013; Roma-Rodrigues *et al.*, 2014). Classical adhesion molecules such as integrins, heparin-glycan proteins and tetraspanins, presented in the exosomes, are necessary for the interaction between exosomes and the surface receptors in the cell and further activation of intracellular signaling (Vaiselbuh, 2015; Villarroya-Beltri *et al.*, 2014). Pro-inflammatory environment may augment the expression of certain receptor molecules such as intracellular adhesion molecule 1 (ICAM-1) at the surface of dendritic cell-derived exosomes, thus increasing the adhesion to antigen-presenting cells or activated T-cells (Kahlert and Kalluri, 2013; Urbanelli *et al.*, 2013). After binding with the cell, exosomes can enter the cell through fusion with the plasma membrane or by different endocytic pathways (Raposo and Stoorvogel, 2013; Svensson *et al.*, 2013). The fusion with the plasma membrane results in the direct release of their inner content into the cytoplasm and it is more likely to occur at acidic conditions, as it happens in tumor microenvironment, because then the fluidity between both membranes is similar than at a neutral pH, where the cell membrane becomes more rigid (Bang and Thum, 2012; Record *et al.*, 2014). Internalization through endocytosis may be made by pinocytosis or phagocytosis, being the latter the most efficient mechanism for uptake of the exosomes, once phagocytic cells have an increased uptake of these vesicles than non-phagocytic cells (Kharaziha *et al.*, 2012; Record *et al.*, 2014). Once exosomes fuse with endosomal compartments their content can be delivered into the cytosol, endoplasmic reticulum or nucleus of recipient cells and exosomes will have one of two outcomes: they can be internalized in endosomes and consequently into MVBs, which will release them into the extracellular environment again or they can fuse with lysosomes and undergo degradation (Record *et al.*, 2014; Zhang *et al.*, 2015).



**Figure 1.8:** Exosome uptake by recipient cells by a) receptors in the surface, b) fusion with the cell membrane or c) phagocytosis (Adapted from Kahlert and Kalluri, 2013).

The internalization of exosomes has been showed by labeling exosomes with PKH26 dye or using fluorescent proteins such as green fluorescent protein (GFP) or red fluorescent protein (RFP) which fuse with marker proteins in the membrane, thus enabling to trace the exosomes. They were visualized by fluorescent microscopy, demonstrating an increased fluorescence inside the cell, thus proving the exosomes' uptake (Suetsugu *et al.*, 2013; Vaiselbuh, 2015). The unique composition of exosomes is critical for their entry in target cells once vesicles composed exclusively by the lipids found in exosomes do not have the capability to fuse with other cells, which indicates that the proteins presented at the exosomes' surface have a critical role in their communication with the surrounding environment (El Andaloussi *et al.*, 2013).

### **1.2.5 EXOSOMES IN BREAST CANCER**

The human mammary gland suffers significant changes after birth, at puberty and pregnancy such as growth and lactation. The mammary gland is composed by a supporting stroma and two epithelial cell types, the luminal cells and the myoepithelial cells, which play different parts in the organization of the mammary gland and milk secretion (Hannafon and Ding, 2013). Exosomes have been identified in breast milk, both colostrum and mature breast milk, and it was demonstrated that they have an important role in the influence of the infants' immune responses (Hannafon and Ding, 2013; Vlassov *et al.*, 2012). Once exomes can transport microRNAs and other biomolecules, it was already suggested that mothers can transfer microRNAs to the newborns through the milk, thus playing their role in the baby's immune system (Hannafon and Ding, 2013).

Several studies have already stated the importance of exosomes in cell-cell communication and consequent transfer of oncogenic information between cells, thus enabling metastatic events and angiogenesis while suppressing the immune system responses (Vaiselbuh, 2015). MicroRNAs secreted by tumor-derived exosomes have been related to the enhancement of the invasion potential in breast malignant cells and because this type of cancer is very heterogeneous with several phenotypic differences between tumors, the profile of exosomal miRNAs may be used as biomarkers (Azmi *et al.*, 2013; Hannafon and Ding, 2013). For instance, miR-21 has been studied has an exosomal biomarker for breast cancer (Vaiselbuh, 2015). Exosomes from this type of cancer express members of the human epidermal receptor (HER) family, constitutively active in many cancer cells, such as HER2 that when over-expressed accounts for 25% of breast cancers (Kahlert and Kalluri, 2013; Marleau *et al.*, 2012). Exosomes released from HER2-positive cancer cells may interfere with anticancer therapies, by resisting to the activity of Trastuzumab, a previously described monoclonal antibody therapy, increasing the tumor proliferation (Braicu *et al.*, 2015; Hannafon and Ding, 2013)

In tumor breast cancer, genetic abnormalities occur mostly in the luminal epithelium, by transition of the normal cells to pre-invasive lesions and also by the loss of myoepithelium cell layer and it was recently demonstrated that the detachment of adherent breast cancer cell leads to the secretion of exosomes (Hannafon and Ding, 2013; Marleau *et al.*, 2012). Despite it is still not totally clarified how exosomes contribute to the development of breast cancer and its progression, exosomes

from breast cancer cells have the ability to convert adipose tissue-derived mesenchymal stem cells into myofibroblasts, which are involved in the remodeling of the tumor microenvironment as well as in angiogenesis (Kahlert and Kalluri, 2013). Nonetheless, it is important to notice that, as previously explained, exosomes also have advantages and the overall power of these nano-sized vesicles remains to be fully understood.

### **1.3 SCOPE OF THE WORK**

The main goal of this thesis is to prevent the release of exosomes by silencing *RAB27A* gene using gold nanoparticles, functionalized with thiolated antisense oligonucleotides, as vectors. Another goal is to isolate and purify exosomes from two different breast cancer cell lines, MCF7 and MDA – MB – 453 using two different methods, characterize them and also to compare the amount of exosomes that could be obtained from each cell line, which can be dependent on certain cell features such as invasive and metastatic capabilities. Furthermore, the last goal is to observe the uptake of tumor-derived exosomes by normal cells, thus allowing us to infer about exosomes' capability of cell-cell communication and biological material transfer by incubating exosomes from MCF7 breast cell line with a normal bronchial/tracheal cell line.

## **2 MATERIAL AND METHODS**

### **2.1 CELL LINES**

The experimental work was performed with two human tumor cell lines, MCF7 (ATCC® HTB-22™) and MDA – MB – 453 (ATCC® HTB-131™), which correspond to mammary adenocarcinoma, purchased from the American Type Culture Collection (“ATCC Cell Lines,” 2014). The cell line MCF7 is from a 69 year old female with breast cancer and MDA cell line is from a 48 year old female with the same disease, being both constituted by adherent epithelial cells.

In order to evaluate the interaction between exosomes and a non-cancerous cell line, Primary Bronchial/Tracheal Epithelial Normal Cells (BTEC) (ATCC® PCS-300-010) derived from normal human lung was used to observe the effect that exosomes from tumor cells had on them (“ATCC Cell Lines,” 2014).

#### **2.1.1 CELL LINE HANDLING AND MAINTENANCE**

The human tumoral cell lines MCF7 and MDA were propagated in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen, USA), supplemented with 10% (v/v) of exosome-depleted Fetal Bovine Serum (exo-FBS; System Biosciences, USA) and 1% (v/v) of antibiotic/antimycotic Penicillin-Streptomycin (Pen-Strep + Antimycotic; Invitrogen, USA). BTEC cell line was propagated in Airway Epithelial Cell Basal Media (ATCC, USA) supplemented with Bronchial Epithelial Cell Growth Kit (ATCC, USA). Cell cultures were maintained in 75 cm<sup>2</sup> culture flasks (BD Biosciences, New Jersey, USA) and were incubated in a CO<sub>2</sub> Incubator (SANYO CO<sub>2</sub> Incubator, Electric Biomedical Co., Osaka, Japan), at 37 °C, 5% (v/v) of CO<sub>2</sub> and an atmosphere of 99% (v/v) humidity.

In order for cells to have the nutrient supply and the space they need to grow, culture cells were renewed when an 80% confluence was reached in the culture flask. After the medium was removed and discarded, 2 mL of trypsin (TrypLE™, Invitrogen, New York, USA) were added to the flask and incubated in the CO<sub>2</sub> Incubator for 5 min so the adherent cells could detach. After that period of time, the same quantity of medium was added to stop the trypsin activity. The cell suspension was transferred to 15 mL Falcons (BD Biosciences, New Jersey, USA) and centrifuged at 1500 rpm for 5 min at approximately 15 °C (Sigma 3-16K 10280, Tuttlingen, Germany). Afterwards, the supernatant was discarded and the remaining pellet was resuspended in 1 mL of fresh medium. To a 75 cm<sup>2</sup> flask it was added 10 mL of fresh medium with a 3x10<sup>5</sup> cells/mL concentration from cell suspension, being after incubated in the previously described conditions. For the exosome purification assays, MCF7 and MDA cell lines were maintained with slightly differences, as described in section 2.4.

Cell density was verified using the trypan blue exclusion method, on a hemacytometer (Hirschmann, Eberstadt, Germany). In a 2 mL eppendorf, 350 µL of medium were added together with

50  $\mu\text{L}$  of the cell suspension and 100  $\mu\text{L}$  of trypan blue solution 4% (v/v) (Sigma), a stain that selectively colors dead cells since it only crosses corrupted membranes. This solution was placed in the hemacytometer and examined at the microscope (Olympus CXX41 inverted microscope Tokyo, Japan). Cell density was determined through the following equation (1):

$$(1) \quad \frac{\text{Number of cells}}{\text{mL}} = \frac{\sum(\text{cells per quadrant})}{4} \times 10^4 \text{ (Chamber Volume } \times \text{ Dilution factor)}$$

### 2.1.2 CELL VIABILITY MTS ASSAY

For each cell line, *in vitro* cytotoxicity assays were performed for each nanoformulation (section 2.2.2 and 2.2.3) and exosome solution (section 2.6) through the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, USA), a colorimetric method for determining the number of viable cells.

After 80% confluence, cells were removed from the flask and centrifuged as previously described in section 2.1.1. The supernatant was discarded and the pellet was resuspended in 1 mL of medium. For cell viability assays, 100  $\mu\text{L}$  of a cell suspension at a concentration of  $0,75 \times 10^5$  cells/mL were plated into 96-well plates (Orange Scientific, Braine-l'Alleud, Belgique) and incubated in the CO<sub>2</sub> Incubator at 37 °C, 5% (v/v) of CO<sub>2</sub> and an atmosphere of 99% (v/v) humidity for 24 hours.

The solutions with gold nanoparticles for MCF7 and MDA cells, as well as the exosomes solutions for BTEC cells were prepared. The medium in the plate was removed and both nanoformulations (section 2.2.2. and 2.2.3.) were added to MCF7 and MDA cells, with 6 and 12 hours of incubation time. As for BTEC cells, these were incubated with exosomes at a concentration of 50  $\mu\text{g}$  for periods of time of 30 min, 2 h, 4 h and 12 h. Control samples were also prepared, incubated with medium only.

After those periods of time, a solution with medium, MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-(carboxymethoxyphenyl)-2-(4-(sulfopheeryl)-2H-tetrazolium, inner salt), and PMS (phenazine methosulfate) in a 100:19:1 ratio was prepared and added to each well for further incubation of 45 min. During this period, a MTS is reduced into formazan by dehydrogenase present in metabolically active cells. The quantity of formazan produced is directly proportional to the number of living cells, measured at 490 nm absorbance by Tecan Infinite F200 Microplate Reader (Tecan, Männedorf, Switzerland) and cell viability was calculated relatively to control samples with the following equation (2):

(2)

$$\text{Cell Viability (\%)} = \frac{\text{Abs 490nm (sample)}}{\text{Abs 490nm (control)}} \times 100$$

The assays were done in triplicate. It was expected to obtain 100% viability in all cases, with the addition of nanoparticles and exosomes to cells since no toxicity is expected.

## 2.2 GOLD NANOPARTICLES

### 2.2.1 GOLD NANOPARTICLES SYNTHESIS

Gold nanoparticles were prepared by a citrate-reduction process first described by Turkevich (Turkevich *et al.*, 1951) and later adapted by Lee and Miesel (Lee and Meisel, 1982). First, all glass material was incubated overnight with *aqua regia* (proportion 1:3 of HNO<sub>3</sub>:HCl) and then washed with milli-Q water. After that, in a 500 mL round bottom flask, 250 mL of 1 mM AuCl<sub>4</sub> (Sigma-Aldrich) were dissolved in milli-Q water and brought to boil in the hot plate. While in reflux, 25 mL of 38.8 mM of sodium citrate (Sigma) were quickly added and the colorless solution turned blue and then to red, which indicates the nanoparticle formation. This solution was protected from light, kept in boil for 30 minutes and then allowed to cool down at room temperature.

AuNPs were later characterized by three methods: (1) UV/Vis Spectroscopy, using an UV/Vis Spectrophotometer (UVmini-1240, Shimadzu, Germany), with the absorbance measurements made using 100  $\mu$ L of volume quartz absorption cells (105.202-QS, Hellma, Germany) and the concentration determined using the Lambert-Beer law (according to the formula  $A = \epsilon \cdot \ell \cdot c$ , where A is the substance absorbance,  $\epsilon$  is the molar absorptivity for the wavelength of A,  $\ell$  is the optical path length and C the solution concentration) with theoretical extinction coefficient ( $2.33 \times 10^8 \text{ M}^{-1}\text{cm}^{-1}$ ); (2) Dynamic Light Scattering (DLS), using a Nanoparticle Analyzer SZ-100 (Horiba Scientific, Japan) at 25 °C and a scattering angle of 90°, with samples of 2 nM of AuNP in milli-Q water previously prepared; (3) Transmission Electron Microscopy (TEM), performed at Instituto de Ciência e Engenharia de Materiais e Superfícies at Instituto Superior Técnico (ICEMS/IST), Portugal, with a HITACHI H-8100 microscope, being the samples prepared by depositing 10  $\mu$ L of the colloidal solution of gold in carbon copper grids, washing twice with milli-Q water, and air dried. The average particle size was determined from TEM pictures using the imaging software Image J, analyzing at least 400 NPs.

## 2.2.2 FUNCTIONALIZATION WITH POLYETHYLENE GLYCOL (PEG)

In order to have stability in biological environment, the AuNP solution (10 nM) was mixed with 0.003 mg/mL of a commercial poly(ethylene glycol) (PEG) [O-(2-Mercaptoethyl)-O'-methyl-hexa(ethylene glycol)] (Sigma-Aldrich, USA) in an aqueous solution of 0.028% of Sodium Dodecyl Sulfate (SDS) (Sigma) and incubated for 16 hours at room temperature while stirring. After that, three centrifugations (14.000 xg, 45 min) (Sigma 3-16K 10280, Tuttlingen, Germany) at 4 °C were performed to remove the excess of PEG which has not been bound, remaining in the supernatant, and it was quantified by the Ellman's Assay. The pellet was re-suspended in Milli-Q water. The resulting functionalized AuNPs were then characterized by UV/Vis Spectroscopy, Dynamic Light Scattering and Transmission Electron Microscopy (Baptista *et al.*, 2013).

The excess of PEG chains in the supernatants is quantified from a calibration curve prepared by reacting 200 µL of a known concentration of O-(2-Mercaptoethyl)-O'-methyl-hexa(ethylene glycol) in 100 µL of phosphate buffer 0.5 M (pH=7) with 7 µL of 5 mg/mL of 5,5'-dithio-bis(2-nitrobenzoic) acid (DTNB) in phosphate buffer 0.5 M (pH=7). Absorbance is measured at 412 nm after 10 min. The amount of PEG chains bounded to the nanoparticles is calculated by the difference between the amount calculated by this assay and the initial amount incubated. Through the Ellman's assay, we were able to determine the number of PEG chains that covers 100% of the gold nanoparticles surface (Appendix A, Figure A.1) *i.e.* 0.01 mg/mL, being able to functionalize the nanoparticles with 30% of PEG in their surface for further functionalization with thiolated oligonucleotides.

## 2.2.3 AuNP@PEG FUNCTIONALIZATION WITH THIOLATED OLIGONUCLEOTIDES

AuNP functionalized with PEG (AuNP@PEG) were therefore functionalized with an antisense Rab27a oligonucleotide in hairpin conformation modified with 5' –thiol- C6 (STABVIDA), previously re-suspended in 1 mL of 0.1 M DL-dithiothreitol (DTT) (Sigma-Aldrich) for 2 hours at room temperature, in order to avoid the dimerization of the oligonucleotides. After the oligonucleotide quantification using the extinction coefficient at 260 nm obtained in Nanodrop, oligomers were added to the AuNP@PEG solution in a 100:1 (AuNP:oligonucleotide) ratio. The solution was purified through a desalting NAP-5 column (Pharmacia Biotech, Sweden) using 10 nM (pH 8) of phosphate buffer as eluent.

To the previous solution it was added an AGE I solution (2% (w/v) SDS, 10 mM phosphate buffer pH 8), sonicated 10 sec in an ultra-sound bath and incubated 20 min at room temperature. Thereafter, it was added an AGE II solution (1,5 M NaCl, 0,01% (w/v) SDS, 10 mM phosphate buffer pH 8) and It was sonicated 10 sec in an ultra-sound bath and incubated 20 min at room temperature with this process being repeated two more times before an incubation for 16 hours at room temperature. After that, the solution containing AuN@PEG@antisense-Rab27a was washed over three centrifugations (14.000 xg, 45 min) to remove the excess of oligonucleotide that did not bound to



the AuNPs. The resulting AuNPs were characterized by Uv/Vis Spectroscopy and Dynamic Light Scattering.

#### **2.2.4 QUANTIFICATION OF FUNCTIONALIZED OLIGONUCLEOTIDES ON AuNPs' SURFACE**

After all washing steps the supernatants were stored so the amount of oligonucleotides per AuNP could be determined. A standard linear calibration curve with known concentrations of oligonucleotide (in the range of 0 – 0.3  $\mu\text{M}$ ) and Quant-iT OliGreen ssDNA Reagent (Thermo Scientific, USA) in phosphate buffer 10 mM pH=8 was prepared (Appendix A, Figure A.2) and the concentration of DNA was measured from fluorescence intensity in the PerkinElmer LS45 Fluorescence Spectrometer (USA) using an Ultra-Micro quartz cell (Hellma, Germany). Fluorescence emission was converted to molar concentration of the oligonucleotide by interpolation from the calibration curve. Once we know the initial amount of oligonucleotide added to the mixture, with the standard curve we can determine what did not bound to the AuNP by subtracting the amount quantified in the supernatants to the initially added.

### **2.3 GENE EXPRESSION EVALUATION ASSAY**

The evaluation of nanoformulations silencing efficacy for *RAB27A* was evaluated by Real-time Quantitative PCR (qPCR), in MCF7 and MDA cell lines. Cells were plated into 24-well plate and were to adhere for 24 hours at 37 °C, 5% (v/v) of CO<sub>2</sub> and an atmosphere of 99% (v/v) humidity. After that period of time, cells were incubated with AuNP@PEG and AuNP@PEG@antisense-Rab27a at an oligonucleotide concentration of 20 nM and 30 nM as well as exosome free medium (control), harvesting the cells after 6 and 12 hours for subsequent RNA extraction (section 2.3.1), cDNA synthesis (section 2.3.2) and gene expression measurement by qPCR (section 2.3.3).

#### **2.3.1 RNA EXTRACTION**

The RNA extraction was performed following the TRIsure Protocol (Bioline, UK). RNA concentration was determined using NanoDrop2000 (Thermo Scientific, USA), by absorbance at 260 nm, knowing that 1 absorbance unit corresponds to 40  $\mu\text{g}$  of single strand RNA in 1 mL. RNA purity was also determined using NanoDrop by  $\text{Abs}_{260}/\text{Abs}_{280}$  and  $\text{Abs}_{260}/\text{Abs}_{230}$  ratios. The ratio  $\text{Abs}_{260}/\text{Abs}_{280}$  must be around 2 so RNA can be considered “pure”; if the ratio is lower than expected, it may indicate the presence of proteins, phenol or other contaminants that absorb at 280 nm (Fleige and Pfaffl, 2006; “SV Total RNA Isolation System,” 2009). The expected values for  $\text{Abs}_{260}/\text{Abs}_{230}$  are

between 2.0 - 2.2. Values lower than those can indicate possible contamination with guanidine thiocyanate (“SV Total RNA Isolation System,” 2009). Samples were stored at -80 °C until further use.

### 2.3.2 cDNA SYNTHESIS

From total RNA, cDNA synthesis was performed by transcriptase reverse enzyme, using NZYtech cDNA synthesis Kit (NZYtech, Portugal), according to their instructions in a S1000™ Thermal Cycler (Bio-Rad, USA). Samples were then quantified in NanoDrop and cDNA concentration was determined by absorbance at 260 nm, knowing that 1 absorbance unit corresponds to 33 µg of single strand DNA in 1 mL. The purity of cDNA was evaluated by  $Abs_{260}/Abs_{280}$  and  $Abs_{260}/Abs_{230}$  ratios. Samples were stored at -20 °C until further use.

### 2.3.3 cDNA AMPLIFICATION BY REAL QUANTITATIVE TIME PCR (qPCR)

In order to analyze the relative changes in *RAB27A* gene expression in the presence and absence of antisense-Rab27a hairpin, it was performed a Real-time Quantitative PCR (qPCR). The internal control used was *RNA18S* gene, a housekeeping gene that codes for ribosomal RNA, used to normalize de expression values of the several samples. The previously synthesized cDNA was used as template of the reaction and a master mix was prepared accordingly to 5x HOT FIREPol® EvaGreen® qPCR Mix Plus (ROX) kit (Solis BioDyne, Estonia) with some modifications, considering a final volume of 20 µL per sample (Table 2.1).

**Table 2.1:** Concentrations used for cDNA template, primers forward and reverse and MgCl<sub>2</sub> for amplification by qPCR.

	Final Concentration	
	Rab27a	18S
5x HOT FIREPol EvaGreen Mix ([MgCl <sub>2</sub> ]=2,5 mM)	1x	1x
cDNA (10 ng/µL)	50 ng	50 ng
Primers forward and reverse (4 pmol/µL)	0,5 µM	0,2 µM
MgCl <sub>2</sub>	4 mM	4 mM

The primers sequences and fragments amplification sizes are shown in Table 2.2 and the reaction conditions are described in Table 2.3, being performed in Cobert Research Rotor-Gene RG3000 (Sigma, USA).

**Table 2.2:** Sequences of the primers used and expected amplification product size.

Gene	Primer Forwrd (5'-3')	Primer Reverse (5'-3')	Amplicon (bp)	Reference
<b>RAB27A</b>	GAAGCCATAGCACTCGGAGAG	ATGACCATTTGATCGCACCA	174	(Dong <i>et al.</i> , 2012)
<b>RNA18S</b>	GTAACCCGTTGAACCCCAT	CCATCCAATCGGTAGTAGCG	151	(Martinez <i>et al.</i> , 2007)

**Table 2.3:** qPCR cycling conditions.

Phase	Temperature (°C)	Time	Cycles
<i>Initial Denaturation</i>	95	15 min	1
<i>Denaturation</i>	95	30 sec	10
<i>Annealing</i>	56	30 sec	
<i>Extension</i>	72	30 sec	
<i>Denaturation</i>	95	30 sec	30
<i>Annealing</i>	57	30 sec	
<i>Extension</i>	72	30 sec	

All amplification products were then separated by gel electrophoresis, in a 2% (w/v) agarose gel (Thermo Scientific, USA), stained with 2% (v/v) of GelRed (10000x) (Biotium, USA), with 100 V for 50 min run in TAE 1x buffer solution (composition TAE 10x: 1.7 M NaCl, 0.03 M KCl, 0.1 M Na<sub>2</sub>HPO<sub>4</sub> and 0.01 M K<sub>2</sub>HPO<sub>4</sub>). Hyperladder IV (Bioline, UK) was used as molecular weight marker. Gel visualization was performed under UV light in *UVIpure* transilluminator (UVITEC, Cambridge, UK), and photographed with a Kodak AlphaDigiDoc camera (Alpha Innotech, California, USA), being the image acquisition performed through AlphaEaseFC *software* (Alpha Innotech, Germany).

Real-time PCR data is analyzed by a relative quantification that describes the change in target gene expression relative to some internal control, like *RNA18S* gene in this case, calculated by  $2^{-\Delta\Delta Ct}$  method. The data analysis was first performed using Ct values of the target gene (*RAB27A*) normalized to control gene (*RNA18S*) using the equation  $\Delta Ct = Ct_{(target)} - Ct_{(control)}$ . Then, to determine

the relative expression levels, the following equation is used:  $\Delta\Delta Ct = \Delta Ct_{(target)} - \Delta Ct_{(control)}$  and after that the expression of the target gene is known by calculation of  $2^{-\Delta\Delta Ct}$  (Livak and Schmittgen, 2001).

## 2.4 EXOSOME EXTRACTION AND PURIFICATION

In order to understand the best method for isolation and purification, exosomes were isolated from two procedures, one based on ultracentrifugations and other on precipitation by the ExoQuick-TC™ Exosome Precipitation Solution (System Biosciences, USA). At a first step, two different supernatants from both MCF7 and MDA cells were collected, in an attempt to observe which one had a better yield of exosome quantity. The two cell lines were propagated in exosome-free medium, at 37 °C in 5% CO<sub>2</sub>, until they were 80% confluent. At that point, the medium in the flasks was collected (“supernatant 1”) and cells were allowed to grow for another 48 hours in fresh exosome-free medium. After that time “supernatant 2” was collected and culture cells were renewed following the procedure described in section 2.1.1. Supernatants were stored at -80 °C until further use.

Isolation by ultracentrifugation method was performed using differential centrifugations followed by ultracentrifugations, as previously described (Koga *et al.*, 2005; Théry *et al.*, 2006), with some modifications. Supernatant 1 (20 mL) was centrifuged at 400 xg for 5 min and 2000 xg for 10 min to remove cells and cellular debris, followed by filtration through a 0.22 µm syringe filter (VWR, USA) so larger vesicles could be retained. Besides the two centrifugations mentioned above, supernatant 2 (20 mL) is submitted to another one at 10.000 xg for 20 min, with no filtration. After samples were treated with centrifugations, ultracentrifugations were performed in a XL-A Analytical Ultracentrifuge (Beckman Coulter USA) with a 30% (w/v) sucrose gradient (30 g sucrose, 2.4 g Tris base, 100 mL D<sub>2</sub>O, pH 7.4) and without sucrose gradient, in order to compare which method gives us the most amount of purified exosomes since exosomes float at densities ranging from 1.15 to 1.19 g/mL on continuous sucrose gradients, different than other vesicles (Théry *et al.*, 2006). Samples were carefully loaded into polycarbonate bottles (Beckman Coulter, USA). Supernatant 1 was submitted to two ultracentrifugations at 100.000 xg for 1 hour, one with 4 mL of sucrose solution followed by another with the sucrose fraction diluted in PBS 1x. If without sucrose gradient, the supernatant is diluted in PBS 1x and only one ultracentrifugation is performed for 1 h and 30 min. Supernatant 2, before being submitted to the same ultracentrifugations previously mentioned, was submitted to an ultracentrifugation at 100.000 xg for 1 hour to remove the larger vesicles once no filtration was performed in this sample. After all ultracentrifugations, the remaining pellets were resuspended in 100 µL of PBS 1x (137 mM NaCl, 2.7 mM KCl, 8 mM NaHPO<sub>4</sub>, 2 mM KH<sub>2</sub>PO<sub>4</sub> pH 7.4). All centrifugations were performed at 4 °C.

Another procedure used to isolate the exosomes was with ExoQuick™ Solution. Supernatants 1 and 2 were centrifuged at 3000 xg for 5 min, pellets were discarded and ExoQuick™ Solution was added to the supernatants (for each final 500 µL it was added 120 µL of ExoQuick™ Solution). Samples were stored overnight at 4 °C and then centrifuged at 1500 xg for 30 min. The supernatant

was removed and the pellet with exosomes was resuspended in PBS 1x. ExoQuick™ Solution was also conjugated with Amicon® Ultra-0.5 Filters (Millipore, Germany), according to manufacturer's instructions, in an attempt to obtain more exosomes from each supernatant.

In order to observe if AuNP@PEG@anitinsen-Rab27a had the expected effect on exosome secretion and also to compare it between the two cell lines used, cells from MCF7 and MDA were plated each into fifteen 35 mm plates and were to adhere for 24 h. After that period of time, cells were incubated for 6 and 12 h with the nanoformulations (sections 2.2.2 and 2.2.3) as well as exosome-free medium as control. Then, medium was collected and it was added fresh exosome-free medium to each plate and collected after one hour. Supernatants of each condition were collected together (total volume of 5 mL each), centrifuged at 3000 xg for 15 min for the removal of cellular debris, filtrated with a 0.22 µm syringe filter to retain larger vesicles and centrifuged in Amicon® Ultra-0.5 Filters according to manufacturer's instructions, so that exosomes were concentrated. Then, to the remaining 500 µL, it was added 120 µL of the ExoQuick™ Solution and stored overnight at 4 °C. The mixture was then centrifuged at 1500 xg for 30 min, the supernatant was removed and the remaining pellet with exosomes was resuspended in PBS 1x.

The protein content was measured in a 96-well plate using Pierce™ BCA Protein Assay Kit (Thermo Scientific, USA). A calibration curve was established using standard Bovine Serum Albumin (BSA) solutions, with concentrations between 0 and 1000 µg/mL. To 10 µL of the exosome sample it was added 150 µL of Pierce reagent and incubated at room temperature for 5 min before the absorbance reading at 660 nm by Tecan Infinite F200 Microplate Reader (Tecan Männedorf, Switzerland). The isolated exosomes were stored at -80 °C until further use.

## **2.5 QUANTIFICATION AND CHARACTERIZATION OF EXOSOMES – WESTERN BLOT**

To verify the presence of exosomes, the pellet with exosomes obtained from the ultracentrifugations and ExoQuick™ Solution was resuspended in a lysis buffer (150 mM NaCl, 2%NP-40, 50 mM Tris pH8, 5 mM EDTA, 2% Protease inhibitor, 10% Phosphatase inhibitor, 1% PMSF and 1% DTT) and incubated for 2 hours. After that, samples were treated SDS loading buffer (1x) (SDS Loading buffer 5x: 0.25% (w/v) bromophenol blue, 500 mM DTT, 20% (v/v) glycerol, 10% (w/v) SDS, 250 mM Tris-HCl pH 6.8) and incubated overnight for further analysis by Western blot. The obtained protein lysates were quantified by Pierce™ BCA Protein Assay Kit, thus determining the protein concentration obtained by ultracentrifugation and ExoQuick™ Solution from supernatants 1 and 2.

In order to understand which method has the better yield, total of protein obtained from ultracentrifugation (15 µg) as well as 15 µg and 50 µg obtained with ExoQuick™ Solution method were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), under

reduction conditions with a stacking gel of 5% (v/v) and a resolving gel of 10% (v/v). Gel was stained with Coomassie blue and the density of the bands was analyzed with GelAnalyser software.

After the analysis of the previous gel a Western Blot analysis was performed with 15 µg, 30 µg and 50 µg of exosomes extracted by ExoQuick™ Solution method from both supernatant 1 and 2 samples. A SDS-PAGE was performed as previously described and proteins were transferred onto a nitrocellulose membrane (Thermo Scientific, USA) at 20 V overnight at 4 °C, using transfer buffer (1x) (Transfer buffer 10x: 25 mM Tris, 192 mM glycine, 0.01% (w/v) SDS, 20% (v/v) methanol, pH 8.3). They were then blocked in TBST buffer (25 mM Tris-HCl, 150 mM NaCl, 0.1% (v/v) Tween-20, pH 7.5) with 5% (w/v) of non-fat milk for 45 min at room temperature. After blocking, the membrane was incubated with primary antibodies Anti-Alix and Anti-CD81 (Novus Biologicals, USA) at a dilution 1:500 and 1:1000, respectively, for 1 h at room temperature, washed three times for 5 min with TBST buffer and incubated 1 h with anti-mouse horseradish peroxidase (HRP)-antibody (Cell Signaling, USA) at a dilution 1:2500. Membranes were then washed three times for 5 min with TBST buffer and the bound antibodies were visualized using Western Bright ECL HRP Substrate (Advansta, USA).

## **2.6 UPTAKE OF EXOSOMES BY NORMAL CELL LINES**

Once exosomes can transfer information from one cell to another, an assay was performed to observe that possibility between tumor-derived exosomes and normal cells. BTEC cells were plated into 35 mm plates with Airway Epithelial Cell Basal Media for 24 h to adhere. They were then incubated in a medium solution with 50 µg of exosomes isolated from tumoral cells (MCF7) for 30 min, 2 h, 4 h and 12 h to be able to compare the expression of *miR-21* and *c-Myc* over time by qPCR. Controls with no exosomes at the same time points were also prepared. A cytotoxicity assay (section 2.1.2) was performed for all the mentioned periods of time to ensure that exosomes did not induce cell death since that could influence the results.

### **2.6.1 EVALUATION OF C-MYC GENE EXPRESSION**

Cells were collected and RNA extracted as explained in section 2.3.1. cDNA was synthesized according to section 2.3.2 and qPCR for *c-Myc* gene expression evaluation was performed as described in section 2.3.3, using the sequence of primers represented in Table 2.4, with *RNA18S* as the internal control.

**Table 2.4:** *c-Myc* primers' sequence and amplification product size.

<b>Gene</b>	<b>Primer Forward (5'-3')</b>	<b>Primer Reverse (5'-3')</b>	<b>Amplicon (bp)</b>	<b>Reference</b>
<i>c-Myc</i>	GCTCATTCTGAAGAGGACTTGT	AGGCAGTTTACATTATGGCTAAAT	229	(Conde <i>et al.</i> , 2010)

### 2.6.1 *MIR-21* QUANTIFICATION

Only a preliminary assay was performed regarding *miR-21* expression, with time points of 30 min and 2 h. After RNA isolation (section 2.3.1), miRCURY LNA™ Universal RT microRNA PCR Kit (Exiqon, Denmark) was used, which is divided in two parts. First, cDNA was synthesized with miRCURY LNA™ Universal cDNA Synthesis Kit II (Exiqon, Denmark), according to manufacturer's instructions, with a final RNA concentration of 5 ng/μL. Cycling conditions were 60 min at 42 °C plus 5 min at 95 °C in the Thermal Cycler (Bio-Rad, USA). Then, a 1:80 dilution of the synthesized cDNA was prepared for RT-PCR analysis at Instituto Nacional de Saúde Dr. Ricardo Jorge (INSA), Portugal, with miRCURA LNA™ SYBR Green Master Mix and LNA PCR primers for *miR-21* (Exiqon, Denmark), using the LightCycler® 480 Instrument (Roche). The internal control used was the gene that codes for U6, a non-coding small nuclear RNA (snRNA) required for nuclear mRNA splicing (Madhani and Guthrie, 1992). Data was analyzed using the  $\Delta\Delta C_t$  method described in section 2.3.3.





### 3 RESULTS AND DISCUSSION


#### 3.1 SYNTHESIS AND CHARACTERIZATION OF GOLD NANOPARTICLES (AuNPs)

Gold nanoparticles (AuNPs) have been demonstrated to play an important role in cancer treatment, acting as nanocarriers. For therapeutic aims, some characteristics of the AuNPs have to be taken into account, such as their size and shape, which can be modulated as desired. The nanoparticles' surface should be large enough to be functionalized with the desired molecules but not too long so nanoparticles can be internalized by the cells and avoid immune responses. The choice for AuNPs is related to their ease of synthesis and functionalization with other biomolecules as well as their good biocompatibility (Silva *et al.*, 2014). Nanoparticles size has been associated to the capping agent citrate since the negatively charged citrate ions on their surface gives them stability and do not allow them to aggregate due to electrostatic repulsion (Sperling and Parak, 2010). For gene silencing, AuNPs should be stable in biological conditions and in order to meet this requirement they were functionalized with PEG. Previous works shown that a 30% saturation of PEG in the particle surface is sufficient to stability and for particles do not aggregate (Sanz *et al.*, 2012).

Nanoparticles with an average diameter of ~14 nm were synthesized by the citrate reduction method and characterized by three different techniques (UV/vis spectroscopy, DLS and TEM) in order to have an accurate analysis of their size before any functionalization. UV/vis spectroscopy is the most usual method for characterizing the nanoparticles, based on their optical properties and SPR (Philip, 2008). By the analysis of the absorbance spectrum (Figure 3.1A) with a wavelength range of 400-800 nm, it was observed a peak at 518 nm, which is in accordance with other works that show that a colloidal solution of Au nanospheres with a diameter around 20 nm has an intense visible light extinction band at 520 nm, giving them their characteristic red color (Baptista, 2012; Jain *et al.*, 2007). A shift of 1nm is observed in AuNP functionalized with PEG indicating an increased size since SPR alters with size, shape and composition (Conde *et al.*, 2012a; Jain *et al.*, 2007), which allow us to verify that the thiol end of PEG biomolecules covalently bounded to the particles surface. As for AuNP functionalized with both PEG and the oligonucleotide, although there is not possible to observe a shift between this and the AuNP@PEG peak, by further DLS analysis (Figure 3.1B) we can infer that the functionalization was successful. Moreover, the core size and morphology of the nanoparticles was confirmed by TEM images analysis (Appendix B, Figure A.3), which demonstrate that the synthesized nanoparticles are spherical with an average size of  $14 \pm 1.25$  nm and AuNP@PEG have an average size of  $15 \pm 1.7$  nm, supporting the results obtained by UV/vis spectroscopy.

Furthermore, DLS measurements were performed in order to obtain a particle size distribution (Figure 3.1B). Particles in a Brownian motion are exposed to a laser and when the light hit the particles, its direction and intensity change according to particle size, due a phenomenon called scattering, which depends on the medium temperature and viscosity (Lim *et al.*, 2013). Usually, DLS results are expressed in terms of Z-average and naked AuNPs were demonstrated to have a

hydrodynamic diameter of  $17.24 \pm 0.35$  nm slightly different from the real size, observed by UV/vis spectroscopy and TEM analysis, due to the presence of an adsorbing layer on the particles' surface (Lim *et al.*, 2013). AuNP@PEG and AuNP@PEG@antisense-Rab27a were shown to have a hydrodynamic diameter of  $20.3 \pm 0.59$  nm and  $30.42 \pm 0.29$  nm, respectively, since molecules on the surface tend to increase the hydrodynamic diameter of particles, confirming the efficacy of functionalization. By fluorescent microscopy it was possible to verify that the number of oligonucleotides per AuNP@PEG was  $96.9 \pm 0.27$  oligonucleotides, closer to the intended 100:1 (AuNP:oligonucleotide) ratio, showing a successful functionalization.



**Figure 3.1:** Characterization of naked gold nanoparticles and functionalized with PEG (AuNP@PEG) and with PEG and antisense-Rab27a (AuNP@PEG@antisense-Rab27a) by A) UV/vis spectroscopy in the wavelength range of 400-800 nm (pH 7.0) with the absorbance peak at 518 nm; and B) DLS measurements with diameter distribution of naked AuNPs (blue), AuNP@PEG (red) and AuNP@PEG@antisense-Rab27a (green).


### 3.2 RAB27A GENE SILENCING (IN MCF7 AND MDA)

Rab GTPases are believed to coordinate several steps in the vesicle trafficking such as budding, mobility, docking and fusion and are commonly over-expressed in cancer cells (Fukuda, 2013; Henderson and Azorsa, 2012). Rab27a protein is believed to be implicated in the exosome secretion pathway, by enabling the docking of MVBs to the plasma membrane and its over-expression has been associated with the invasive and metastatic potential of human breast cancer cells (Ostrowski *et al.*, 2010; Wang *et al.*, 2008). Therefore, the synthesized AuNPs were used as vehicles for the delivery of an antisense oligonucleotide to silence *RAB27A* gene expression in an attempt to prevent exosome secretion in two breast cancer cell lines. The synthesized thiolated oligonucleotide in

a hairpin conformation is expected to hybridize with the complementary mRNA thus preventing the translation into the Rab27a protein, as described in section 1.1.3.1.1.


In order to identify the best oligonucleotide concentration for an enhanced silencing, an assay in MCF7 cell line was performed with 20 nM and 30 nM of AuNP@PEG@antisense-Rab27a, with exposure times of 6 and 12 hours. Cells were also incubated with AuNP@PEG for control and RNA extraction and cDNA synthesis were performed, being the respective cDNA used as template for gene expression evaluation. Through qPCR, genes were amplified and Ct values obtained for further analysis with normalization to the internal control *RNA18S* and subsequent normalization to control samples (only exosome-depleted medium and no nanoparticles' addition). Gene expression variation is calculated through  $2^{-\Delta\Delta Ct}$  and values above 1 are considered to be over-expression and under 1 are considered under-expression (Livak and Schmittgen, 2001). qPCR technique was optimized for Rab27a detection, being the final concentration of  $MgCl_2$  increased to 4 nM and the primers boiled in order to prevent the formation of secondary structures that would affect the reaction.

In the presence of the complementary target sequence, the stem-loop single stranded oligonucleotide will open and hybridize with it, forming a double-stranded structure, thus inhibiting the mRNA translation into Rab27a protein. As we can observe in Figure 3.2, there is a decrease in gene expression, both with 20 nM and 30 nM, but it is noticeable that the AuNP@PEG@antisense-Rab27a with a 20 nM concentration induces downregulation more noticeable than at 30 nM after 12 hours, meaning that in this case the inhibition capacity is lower with higher concentrations. This seems to be the contrary the common sense and to other reports (Conde *et al.*, 2010).



**Figure 3.2:** *RAB27A* gene expression evaluation in MCF7 cells incubated with AuNP@PEG and AuNP@PEG@antisense-Rab27a with concentrations of 20 nM and 30 nM. Gene expression variation is calculated through  $2^{-\Delta\Delta Ct}$ , after normalization with *RNA18S* gene and control cells (exosome-depleted medium). The data are represented as means  $\pm$  SEM of at least three independent experiments.


Based on the results above, the assays proceeded with AuNP@PEG@antisense-Rab27a at a 20 nM concentration. Both MCF7 and MDA cell lines were incubated with AuNP@PEG and AuNP@PEG@antisense-Rab27a for 6 and 12 hours, to evaluate the effect of the antisense oligonucleotide against *RAB27A* gene in different cell lines. Comparing MCF7 and MDA cells, it was possible to verify that the metastatic MDA cells have an increased expression of *RAB27A* gene, as it was expected, since it is involved in the modulation of invasive and metastatic phenotypes in breast cancer cells (Hendrix and de Wever, 2013). An increase in gene expression, relatively to control cells, is observed when cells are incubated with AuNP@PEG in MCF7 cells after 12 hours exposure and in MDA after 6 and 12 hours exposure (Figure 3.3). Once Rab proteins are responsible for the coordination of several steps in the intracellular trafficking (Fukuda, 2013), this over-expression might be a consequent of the nanoparticles' internalization that possibly cause some disturb in the endocytic pathway. As for incubation with AuNP@PEG@antisense-Rab27a, in MCF7 cells (Figure 3.3A) there is only possible to observe a decrease in *RAB27A* gene expression at 12 h, not being significantly altered after 6 h exposure. However, in MDA cells (Figure 3.3B), it is possible to observe a more significant decrease in *RAB27A* gene expression after exposure of 6 hours. If we were to compare gene expression with cells exposed to AuNPs, utilizing cells incubated with AuNP@PEG as control, it is possible to observe that *RAB27A* is under-expressed in every condition. These results allow us to conclude that gold nanoparticles functionalized with antisense oligonucleotides were internalized by cells and acted as inhibitors of gene expression, as it was expected.



**Figure 3.3:** *RAB27A* gene expression evaluation in MCF7 cells (A) and MDA cells (B) incubated with AuNP@PEG and 20 nM of AuNP@PEG@antisense-Rab27a for 6 h and 12 h. Gene expression variation is calculated through  $2^{-\Delta\Delta C_t}$ , after normalization with *RNA18S* gene and control cells (exosome-depleted medium). The data are represented as means  $\pm$  SEM of at least three independent experiments.

In order to evaluate whether the nanoformulations had some toxic effect on cells, a cell viability assay was performed. Cell survival rates upon nanoparticles exposure were determined via the MTS assay (section 2.1.2) on MCF7 and MDA cells, with the same experimental conditions. Observing Figure 3.4, no toxicity was detected after 6 and 12 h incubation, as expected, since gold

nanoparticles have already been demonstrated to have reduced toxicity in biological environment when functionalized with PEG molecules and antisense oligonucleotides (Conde *et al.*, 2012b).



**Figure 3.4:** Cell viability in MCF7 and MDA cells after incubation with AuNP@PEG and AuNP@PEG@antisense-Rab27a with exposure times of 6 h (A) and 12 h (B). Cell viability values were normalized in relation to the control group without exosomes. The data are represented as means  $\pm$  SEM of at least two independent experiments.


With the view to verify if the observed decrease in *RAB27A* gene expression when cells are incubated with AuNP@PEG@antisense-Rab27a corresponds to a decreased amount of exosomes released by MCF7 and MDA cells, this parameter was further evaluated.

### 3.3 EXOSOME QUANTIFICATION

#### 3.3.1 COMPARISON BETWEEN ISOLATION METHODS – ULTRACENTRIFUGATION AND EXOQUICK™ SOLUTION

Until now, few attempts have been performed on the exosome isolation optimization from human plasma once it is a more challenging type of sample as it has high levels of clotting factors and additional proteins that might difficult the exosome isolation (Muller *et al.*, 2014). In the present work, exosomes were isolated from MCF7 cells' medium by two different methods, ultracentrifugation and ExoQuick™ Solution, described in section 2.4. Traditional processes for exosome isolation from cell culture medium are tedious and difficult, typically based on ultracentrifugation processes that are usually combined with sucrose gradients since exosomes have floating densities different than other vesicles (Théry *et al.*, 2006). Within the last few years several reagents have been commercially available for exosome isolation and purification ("Exosome Research," 2015). ExoQuick™ Solution is a polymer-based method that gently precipitates the exosomes by forming a network that captures vesicles with sizes between 60 and 150 nm, providing a rapid and efficient method for exosome isolation ("Exosome Research," 2015).


Contrary to expectations, it was observed that when using ultracentrifugation with sucrose gradient there was a small amount of isolated exosomes in both supernatants 1 and 2 ( $22.4 \pm 5 \mu\text{g}$  of protein/mL and  $34.5 \pm 8 \mu\text{g}$  of protein/mL, respectively) (Figure 3.5). Exosomes were quantified based on the samples protein content, measured with Pierce™ BCA Protein Assay Kit and this loss of protein might be caused by the formation of exosome aggregates in the presence of sucrose gradient, leading to a large exosome lost (Muller *et al.*, 2014). Attending to Figure 3.5, supernatant 2 either isolated using sucrose gradient or not, yields a greater amount of exosomes. This could be due to the fact that this supernatant is collected when the culture is with more than 100% cell confluence compared with supernatant 1 (80% confluence). At 100% confluency, cells are under more stress because there is not enough nutrients and space for survival and it was demonstrated that in stress conditions, where the lack of oxygen and nutrients prevail, cells secrete more exosomes (Villarroya-Beltri *et al.*, 2014). Besides, the isolation method was different between the two supernatants. Supernatant 2 was submitted to one more ultracentrifugation and no filtration, which might lead to a not so purified sample, with the presence of other vesicles and thus more proteins could have been quantified.



**Figure 3.5:** Exosome quantification ( $\mu\text{g/mL}$ ) of both supernatant 1 and 2 after isolation by ultracentrifugation method, with and without sucrose gradient. The data are represented as means  $\pm$  SEM of at least two independent experiments; \* $p < 0.05$  as compared with ultracentrifugation with sucrose values.

Unlike ultracentrifugation method, Exoquick™ Solution has several benefits such as the capacity of faster and simpler exosome isolation, no need for special equipment such as an ultracentrifuge and it allows working with small sample volumes (“Exosome Research,” 2015). In previous works it was demonstrated that ExoQuick™ Solution is a more efficient method than ultracentrifugations without sucrose gradients, when analyzed by Nanoparticle Tracking Analysis (NTA) (King *et al.*, 2012). In the present work the same result was not accomplished but it is important to notice that only one assay was performed with ExoQuick™ Solution for exosome isolation from

supernatants 1 and 2. Both supernatants were treated in the same way, being submitted to centrifugation and filtration through a 0.22  $\mu\text{m}$  syringe filter. Before the addition of the ExoQuick™ Solution, centrifugations were performed with and without the Amicon® Ultra-0.5 filters in an attempt to improve the exosome recovery, once these filters provide fast ultrafiltration, allowing high sample recoveries (Millipore, 2012). Contrary to what happens in isolation by ultracentrifugation, with ExoQuick™ Solution there is a greater amount of isolated exosomes from supernatant 1 than from supernatant 2 but this difference might be due to the fact that only one assay was performed, which might lead to errors. Observing Figure 3.5 and 3.6, it is possible to see that ultracentrifugation without sucrose gradient provided a greater amount of isolated exosomes than ExoQuick™ Solution (average of  $446.3 \pm 42 \mu\text{g}$  of protein/mL vs  $239.8 \pm 80.9 \mu\text{g}$  of protein/mL, respectively). However, one can conclude that ExoQuick™ Solution combined with the Amicon® Filters is the most efficient method tested in the present work, with a 6 times greater amount of isolated exosomes compared to the isolation without the filters, with an average of  $2684.87 \pm 145 \mu\text{g}$  of protein/mL contrary to the  $446.3 \pm 42 \mu\text{g}$  of protein/mL obtained by ultracentrifugation without sucrose gradient. Attending these results and being a less time consuming method, ExoQuick™ Solution combined with Amicon® Ultra-0.5 filters was the chosen method for exosome isolation in the following assays.




**Figure 3.6:** Exosome quantification ( $\mu\text{g}/\text{mL}$ ) after isolation by ExoQuick™ Solution, with and without Amicon® Ultra-0.5 Filters.

### 3.3.2 EXOSOME QUANTIFICATION IN MCF7 AND MDA CELLS

Breast cancer is very heterogeneous (Hannafon and Ding, 2013) and although the cell lines under study are both breast cancer cell lines they are very different from each other. Cancer cells do not have the same ability to metastasize, to modify their adhesion to the extracellular matrix thus allowing the escape from the tumor site (Zhang *et al.*, 2013). While MCF7 cells form cohesive

structures, exhibiting cell-cell adhesions, thus being tumorigenic but non-metastatic, MDA – MB – 453 cells on the other hand do not have cohesive structures, instead have grape-like or stellate structures with a more deformable cytoskeleton and altered adhesion thus being spontaneously metastatic (Holliday and Speirs, 2011). Exosomes are secreted by most cell types and invasive cells, like MDA cells, have been correlated to an increased exosome secretion since in stress situations cells release exosomes so they modulate the surrounding environment and promote angiogenesis thus enabling cell survival and migration (Muralidharan-Chari *et al.*, 2010).

Exosome secretion between MCF7 and MDA cells was compared and the effect of the antisense oligonucleotide analyzed for both cell lines comparing the amount of secreted exosomes in each condition. For a 6 h period, cells were incubated with exosome-free medium so no external exosomes could influence the assay, and also with AuNP@PEG and AuNP@PEG@antisense-Rab27a. After, cells were incubated with fresh exosome-free medium for 1 h so the effect of the functionalized nanoparticles could be visualized and the amount of secreted exosomes could be compared. The medium was collected and cells from each condition were counted by the Trypan blue exclusion method described in section 2.1.1. Observing Figure 3.7, it is possible to affirm that, as expected, MDA cells secrete larger amounts of exosomes than MCF7 cells.




**Figure 3.7:** Quantification of exosomes in MCF7 and MDA cells after isolation with ExoQuick™ Solution. The data are represented as means ± SEM of at least two independent experiments.

Figure 3.8 represents the percentage of exosomes, relatively to control cells, considering the cell number in each condition. Incubation with AuNP@PEG demonstrated to lead to a small decrease in the amount of the secreted exosomes of 13.9% and 16% in MCF7 and MDA cells, respectively, what might be due to effects of internalization of the nanoparticles that can interfere with exosome secretion but the lack of literature reporting the exosome efflux and nanoparticle interaction hampers to substantiate the previous statement. Gold nanoparticles have been considered to be good vehicles



for gene regulation since they can be functionalized with several biomolecules and protect them against nuclease degradation (Doria et al., 2010). As expected, it was verified that AuNP@PEG@antisense-Rab27a leads to a decrease in the exosome secretion in both cell types in study, with a greater effect in MDA cells of almost 50% difference.




**Figure 3.8:** Quantification of exosomes in MCF7 and MDA cells when incubated with AuNP@PEG and AuNP@PEG@antisense-Rab27a. The data are represented as means  $\pm$  SEM of at least two independent experiments; \* $p < 0.005$ , as compared with the control group. The values were normalized in relation to the MCF and MDA control group without AuNP (only exosome-depleted medium).

The interest in exosomes has been growing exponentially and their involvement in cancer progression has already been proved. These promising results that demonstrates the ability of the antisense oligonucleotides carried out by gold nanoparticles in reducing *RAB27A* gene expression hence reducing the exosome secretion, can be the beginning of new cancer therapy strategies for control of these vesicles' release, which could lead to a decrease of tumor dissemination.

### 3.3.3 CHARACTERIZATION OF EXOSOMES - WESTERN BLOT

To ensure that the purified vesicles were in fact exosomes and not other contaminating material, samples were characterized by a Western blot analysis, using Anti-Alix antibody. Based on their endosomal origin, exosomes exhibit multiple proteins involved in MVB formation (Alix), in membrane transport and fusion (actin, Rab proteins) and tetraspanins (CD63, CD81), among others, independent of their cell of origin, thus those proteins can be used as exosomal biomarkers (Vlassov et al., 2012).


First, a SDS-PAGE was performed with exosomes lysates from supernatants 1 and 2 obtained by ultracentrifugation and ExoQuick™ Solution in order to detect which method has a better yield in terms of protein concentration. 15 µg of exosomes obtained by ultracentrifugation as well as 15 µg and 50 µg obtained by ExoQuick™ Solution were loaded into the wells. In Figure 3.9, several proteins with different molecular weights can be distinguished and ExoQuick™ Solution was demonstrated to have a better yield, even with the same protein concentration of exosomes lysates from ultracentrifugation. Therefore, a Western blot was performed with 15 µg, 30 µg and 50 µg of exosome lysates samples obtained with ExoQuick™ Solution for further characterization.



**Figure 3.9:** SDS-PAGE gel stained with Coomassie blue. Samples loaded into wells 1 and 2 correspond to exosomes lysates extracted from supernatants 1 and 2 by ultracentrifugation. Samples from the 3<sup>rd</sup> to the 6<sup>th</sup> well correspond to exosome lysates extracted from supernatants 1 and 2 by Exoquick Solution.

Alix is a protein presented in exosomes involved in the budding of the membrane in the ILVs formation and hence it can be used as marker for the identification and confirmation of exosome presence (Roma-Rodrigues *et al.*, 2014). With a 96 kDa molecular weight, Alix protein was demonstrated to be present in samples, with a better yield when a 50 µg concentration was used, both in supernatant 1 and 2 (Figure 3.10). That presence demonstrates that the isolated vesicles were in fact the expected exosomes. Furthermore, in order to an accurate exosome characterization, Anti-CD81 was also used since CD81 is a membrane-associated protein involved in the process of ILVs formation as well, thus being used as exosomal marker too (Chiba *et al.*, 2012; Roma-Rodrigues *et al.*, 2014). Since CD81 has a low molecular weight (26 kDa) (Chiba *et al.*, 2012), no signal was

obtained. Observing the previous SDS-PAGE (Figure 3.9) it is possible to see that no proteins appear around the expected size for CD81 protein in any condition what might be the consequence of low CD81 concentration in samples, thus leading to the absence of signal when membranes were incubated with Anti-CD81.



**Figure 3.10:** Western blot analysis of Alix protein in different amount of exosomes purified from supernatant 1 and 2 by ExoQuick Solution. Samples 1, 3 and 5 correspond to supernatant 1; samples 2, 4 and 6 correspond to supernatant 2. (M= molecular weight marker. NZYColour Protein Marker II).

### 3.4 UPTAKE OF EXOSOMES BY NORMAL CELLS


The potential role of tumor-derived exosomes in cancer progression must be considered. When exosomes are secreted from cells to the extracellular space, they can either travel through body fluids or be internalized by other cells, either neighborhood or distant cells, thus enabling the transfer of biomolecules between cells (Roma-Rodrigues *et al.*, 2014). This information exchange can lead to modifications in the cells' phenotype. For instance, tumor-derived exosomes can transfer oncogenic features and miRNAs thus being capable of transforming the normal cells into tumoral cells (Record *et al.*, 2011). To observe this cell-cell communication, BTEC cells were incubated with 50 µg of MCF7-derived exosomes and variations in both *c-Myc* and *miR-21* gene expression were analyzed.

#### 3.4.1 C-MYC GENE EXPRESSION


*c-Myc* oncogene is involved in cellular processes such as replication, differentiation and apoptosis. In normal cells, *c-Myc* expression is highly regulated and the protein levels are low while in most types of human cancer it has been shown to be overexpressed (Miller *et al.*, 2013). Exosomes contain a set of biomolecules, such as proteins, RNA and DNA, thus being able to transfer genetic information from one cell to another (Kahlert and Kalluri, 2013). For this reason, *c-Myc* expression was evaluated upon exposure of normal cells to tumor-derived exosomes, in an attempt to demonstrate

the information transfer between exosomes and other cells, thus providing the exchange of oncogenic features, which might lead to tumor dissemination.

After RNA extraction and cDNA synthesis, a qPCR was performed and Ct values were analyzed with normalization to the internal control *RNA18S* and further normalization to control samples, which had not been incubated with tumor-derived exosomes. Observing Figure 3.11, it is possible to notice that *c-Myc* expression slightly increases at 30 min and 2 hours and it is highly over-expressed after BTEC cells were incubated in the presence of MCF7 exosomes for 4 and 12 hours when comparing to the normal intracellular expression (Figure 3.12A). This data leads us to believe that the uptake of exosomes occurred as *c-Myc* expression is very different from its expression in cells with no exosomes (Figure 3.12A), which allows us to prove that exosomes can transfer oncogenic information between cells, even between different cell lines, with different characteristics, being one of them normal and the other malignant. Figure 3.12B demonstrates the *c-Myc* expression in MCF7 cells and it is possible to observe that gene expression does not have a significant change at 30 min and 2 hours but after 4 and 12 hours, gene expression is increased. Comparing both figures, BTEC cells that received the exosomes (Figure 3.11) have an increased expression of *c-Myc* gene than BTEC cells in normal conditions (Figure 3.12A) and MCF7 cells (Figure 3.12B). This could be explained by the fact that in normal conditions, BTEC cells do not express *c-Myc* and when incubated with the MCF7-derived exosomes there is a transfer of the DNA molecules from the tumoral cells to the normal cells resulting in an increase in *c-Myc* expression in BTEC cells with tumor-derived exosomes.



**Figure 3.11:** *c-Myc* gene expression evaluation in BTEC cells after incubation with 50  $\mu$ g of MCF7-derived exosomes. Data was normalized relatively to *RNA18S* gene expression and subsequent normalization with BTEC cells that were not exposed to MCF7-derived exosomes. The data are represented as means  $\pm$  SEM of at least two independent experiments.




**Figure 3.12:** Intracellular *c-Myc* gene expression in BTEC cells (A) and MCF7 cells (B). Data analyzed relatively to *RNA18S* gene expression. The data are represented as means  $\pm$  SEM of at least two independent experiments; \* $p < 0.005$ , as compared with *c-Myc* expression at 30 min.

### 3.4.2 *MIR-21* QUANTIFICATION


Micro-RNAs, with 17 to 24 nucleotides in length, are implicated in post-transcriptional modifications by binding to mRNAs thus regulating their expression and/or degradation (Azmi *et al.*, 2013). Circulatory miRNAs are being studied as biomarkers for cancer since their secretion can be mediated by exosomes, that protect them from degradation by RNase enzymes, thus remaining functional when transported to other cells (Gajos-Michniewicz *et al.*, 2014). miRNAs are able to influence the expression of genes within their cell of origin but also can affect genes in other cells, distant or not, and have been shown to be over-expressed in several cancers (Azmi *et al.*, 2013; Gajos-Michniewicz *et al.*, 2014). *miR-21* is a microRNA that acts as an oncogene (oncomiR), by silencing an antiapoptotic gene, thus contributing to cell survival (Gajos-Michniewicz *et al.*, 2014).

Alterations in *miR-21* gene expression were also evaluated in BTEC cells incubated with MCF7-derived exosomes, with normalization to constitutive miRNA U6 and subsequent normalization to control cells. Due to time constraints, only one assay was performed, being *miR-21* expression only analyzed in cells exposed to the isolated exosomes for 30 min and 2 hours. Although this is a preliminary assay, with no replicates, it is possible to observe in Figure 3.13 that no expression is observed after 30 min but there is an accentuated over-expression of *miR-21* gene in BTEC cells incubated with the tumor-derived exosomes, being this over-expression of microRNAs already demonstrated by Singh and colleagues in a human mammary epithelial cell line when the uptake of MDA-derived exosomes occurred (Singh *et al.*, 2014). This event corroborates the results in section 3.4.1, once the observed deregulation of *miR-21* expression in BTEC cells is not normal and can be explained by the transfer of oncogenic information via the exosomes.



**Figure 3.13:** *miR-21* expression variations in BTEC cells after incubation for 30 min and 2 h with 50 µg of MCF7-derived exosomes, with normalization to miRNA U6. Only one experiment was performed.

In order to evaluate if the uptake of the tumor-derived exosomes had some toxicity effect on cells that lead cells to death, a cell viability assay was performed. Cell survival rates upon exosome exposure were determined via the MTS assay (section 2.1.2) on BTEC cells, with the same experimental conditions. Since exosomes are biological molecules constantly being secreted by either normal or malignant cells, no toxicity was expected to happen when exosomes were transferred to BTEC cells. Like anticipated, no cell death was significantly detected after all the incubation times, having all the conditions approximately 100% viability relatively to control cells, with no exosomes from MCF7 cells (Figure 3.14).



**Figure 3.14:** Cell viability in BTEC cell line incubated with 50 µg of tumor-derived exosomes. Cell viability values were normalized in relation to the control group without exosomes. The data are represented as means  $\pm$  SEM of at least two independent experiments.

#### 4 CONCLUSIONS AND FUTURE PERSPECTIVES

Cancer is a disease that affects millions of people around the world and in order to fight it several new therapy approaches have been studied since traditional cancer treatments must be improved. Although exosomes play a part in the removal of cell debris during cell maturation process and participate in the immune system responses and tissue repair, they have been implicated in cancer since they were demonstrated to contribute to tumor growth and metastasis, as well as angiogenesis promotion and also triggering of immunosuppressive responses. Exosomes can transfer information between cells and those released by cancer cells are able to provide oncogenic features to normal cell, modulating their phenotype, thus promoting the tumor dissemination. In an effort to stop this evasion and tumor growth, the therapy strategy approached in the present work relies on the prevention of the exosomes' secretion, which is mostly coordinated by Rab27a protein.

Gold nanoparticles with an average diameter of 14 nm were synthesized and functionalized with PEG molecules in order to be stable in biological environment and further with antisense oligonucleotides designed against *RAB27A* sequence to down-regulate Rab27a protein expression and consequently reduce the exosome secretion. The nanoformulations were incubated together with MCF7 and MDA cells and by qPCR it was demonstrated that, as expected, *RAB27A* expression was decreased in MDA cells after 6 and 12 hours of exposure and in MCF7 cells after 12 hours. These results demonstrate that the gold nanoparticles with the oligonucleotide in hairpin had the expected effect of reducing the *RAB27A* gene function, what will presumably lead to the prevention of exosomes secretion. Gold nanobeacons, i.e. AuNPs functionalized with fluorophore labeled hairpin-DNA are also an available approach to track cell internalization and visualize directly the effective silencing (Conde et al., 2013).

The best method for exosome isolation from supernatants 1 and 2 was revealed to be ExoQuick™ Solution together with Amicon® Ultra-0.5 filters, having been isolated an average of  $2684.87 \pm 145$  µg of protein/mL in contrast to the  $446.3 \pm 42$  µg of protein/mL obtained by ultracentrifugation. Adding a sucrose gradient to ultracentrifugations revealed to be, contrary to expectations, the method with the poorest yield in terms of amount of isolated exosomes. Comparing exosome secretion between the two breast cell lines in study, MDA cells, with an invasive phenotype, were shown to secrete more exosomes than MCF7 cells. Furthermore, when cells were exposed to AuNP@PEG@antisense-Rab27a it was observed a significant decrease in the amount of secreted exosomes, comparing with cells incubated with AuNP@PEG and control cells. The confirmation that these isolated vesicles were definitely exosomes was performed by Western blot analysis. The exosomal protein Alix was demonstrated to be present, which lead us to the conclusion that the isolated vesicles were indeed exosomes. CD81, another protein marker, was also used to accurate the exosome characterization but due to protein concentrations it was not able to be visualized. Further confirmations through techniques such as Transmission Electron Microscopy (TEM) could have been made but do to time constraints it was not possible.

The uptake of MCF7-derived exosomes by BTEC cells was confirmed by the analysis of *c-Myc* and *miR-21* expression by qPCR. Once both genes were over-expressed in BTEC cells that received the tumor-derived exosomes, one can conclude that exosomes are able to pass molecules from one cell to another within 12 hours. To learn about the exosome uptake is also very usual to label exosomes with small molecule fluorophores such as PKH67 and PKH26 allowing the monitorization of the exosome uptake by recipient cells (Suetsugu *et al.*, 2013).

In the present work no more studies were able to be finished due to time constraints once it was necessary to optimize the exosome isolation for the following assays and also the analysis by qPCR with Rab27a primers. Nanomedicine offers tools to diagnose and treat cancer, with nanoparticles being used for gene silencing therapies and drug delivery, as it was demonstrated to have great efficacy and (almost) no toxicity. The study of exosomes in cancer research is a relatively new area and, despite the advances, much needs to be learnt about their involvement in both positive and negative aspects of health. Being natural transporters, using exosomes for targeted delivery can be beneficial in future works, as well as an accurate characterization of exosomes and a better comprehension of exosome uptake and information exchange.



## 5 REFERENCES

- Akers, J.C., Gonda, D., Kim, R., Carter, B.S., Chen, C.C. 2013. Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. *J. Neurooncol.* 113: 1–11.
- Alexis, F., Pridgen, E.M., Langer, R., Farokhzad, O.C. 2010. Nanoparticle Technologies for Cancer Therapy, Drug Delivey.
- Alkilany, A.M., Murphy, C.J. 2010. Toxicity and cellular uptake of gold nanoparticles: What we have learned so far? *J. Nanoparticle Res.* 12: 2313–2333.
- American Cancer Society 2014. What are the key statistics about breast cancer? *Cancer.org*. URL <http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-key-statistics> (accessed 8.10.15).
- Anand, P., Kunnumakara, A.B., Sundaram, C., Harikumar, K.B., Tharakan, S.T., Lai, O.S., Sung, B., Aggarwal, B.B. 2008. Cancer is a preventable disease that requires major lifestyle changes. *Pharm. Res.* 25: 2097–2116.
- ATCC Cell Lines 2014. URL [www.lgcstandards-atcc.org/Products/Cells\\_and\\_Microorganisms/Cell\\_Lines.aspx](http://www.lgcstandards-atcc.org/Products/Cells_and_Microorganisms/Cell_Lines.aspx) (accessed 1.8.15).
- Azmi, A.S., Bao, B., Sarkar, F.H. 2013. Exosomes in cancer development, metastasis, and drug resistance: A comprehensive review. *Cancer Metastasis Rev.* 32: 623–642.
- Bang, C., Thum, T. 2012. Exosomes: New players in cell-cell communication. *Int. J. Biochem. Cell Biol.* 44: 2060–2064.
- Baptista, P., Conde, J., Rosa, J. 2013. Gold-Nanobeacons as a theranostic system for the detection and inhibition of specific genes. *Protoc. Exch.* 1–35.
- Baptista, P.V. 2012. Could gold nanoprobess be an important tool in cancer diagnostics? *Expert Rev. Mol. Diagn.* 12: 541–3.
- Bellingham, S.A., Guo, B.B., Coleman, B.M., Hill, A.F. 2012. Exosomes: Vehicles for the transfer of toxic proteins associated with neurodegenerative diseases? *Front. Physiol.* 3:124.
- Bergers, G., Benjamin, L.E. 2003. Tumorigenesis and the angiogenic switch. *Nat. Rev. Cancer* 3: 401–410.
- Bertram, J.S. 2001. The molecular biology of cancer. *Mol. Aspects Med.* 21: 167–223.
- Bobrie, A., Krumeich, S., Reyat, F., Recchi, C., Moita, L.F., Seabra, M.C., Ostrowski, M., Théry, C. 2012. Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression. *Cancer Res.* 72: 4920–4930.
- Braicu, C., Tomuleasa, C., Monroig, P., Cucuianu, A., Berindan-Neagoe, I., Calin, G. a 2015. Exosomes as divine messengers: are they the Hermes of modern molecular oncology? *Cell Death Differ.* 22: 34–45.
- Cancer Research UK 2015. Cancer Research UK URL <http://www.cancerresearchuk.org> (accessed 8.10.15).
- Chiba, M., Kimura, M., Asari, S. 2012. Exosomes secreted from human colorectal cancer cell lines contain mRNAs, microRNAs and natural antisense RNAs, that can transfer into the human hepatoma HepG2 and lung cancer A549 cell lines. *Oncol. Rep.* 28: 1551–1558.

- Conde, J., Ambrosone, A., Sanz, V., Hernandez, Y., Marchesano, V., Tian, F., Child, H., Berry, C.C., Ibarra, M.R., Baptista, P. V., Tortiglione, C., de la Fuente, J.M. 2012a. Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing. *ACS Nano* 8316–8324.
- Conde, J., de la Fuente, J.M., Baptista, P. V 2010. In vitro transcription and translation inhibition via DNA functionalized gold nanoparticles. *Nanotechnology* 21: 505101.
- Conde, J., Doria, G., Baptista, P. 2012b. Noble metal nanoparticles applications in cancer. *J. Drug Deliv.* 2012: 751075.
- Conde, J., Larginho, M., Cordeiro, A., Raposo, L.R., Costa, P.M., Santos, S., Diniz, M.S., Fernandes, A.R., Baptista, P. V 2014. Gold-nanobeacons for gene therapy: evaluation of genotoxicity, cell toxicity and proteome profiling analysis. *Nanotoxicology* 8: 521–32.
- Conde, J., Rosa, J., de la Fuente, J.M., Baptista, P. V 2013. Gold-nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events. *Biomaterials* 34: 2516–23.
- Crawford, S. 2013. Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. *Front. Pharmacol.* 4 1–18.
- Cross, D., Burmester, J.K. 2006. Gene therapy for cancer treatment: past, present and future. *Clin. Med. Res.* 4: 218–227.
- Dawson, M. a., Kouzarides, T. 2012. Cancer epigenetics: From mechanism to therapy. *Cell* 150: 12–27.
- Denzer, K., Kleijmeer, M.J., Heijnen, H.F., Stoorvogel, W., Geuze, H.J. 2000. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. *J. Cell Sci.* 113: 3365–3374.
- Devi, P. 2004. Basics of carcinogenesis. *Heal. Adm* 16–24.
- Doherty, G.J., McMahon, H.T. 2009. Mechanisms of endocytosis. *Annu. Rev. Biochem.* 78: 857–902.
- Doria, G., Baumgartner, B.G., Franco, R., Baptista, P. V 2010. Optimizing Au-nanoprobes for specific sequence discrimination. *Colloids Surf. B. Biointerfaces* 77: 122–4.
- El Andaloussi, S., Lakhal, S., Mäger, I., Wood, M.J. a 2013. Exosomes for targeted siRNA delivery across biological barriers. *Adv. Drug Deliv. Rev.* 65: 391–7.
- Esteller, M. 2008. Molecular Origins of Cancer Epigenetics in Cancer. *N Engl J Med* 358: 1148–59.
- ExoCarta 2015. URL <http://exocarta.org> (accessed 8.18.15).
- Exosome Research 2015. . *Syst. Biosci.*
- Fader, C.M., Colombo, M.I. 2009. Autophagy and multivesicular bodies: two closely related partners. *Cell Death Differ.* 16: 70–78.
- Fichou, Y., Fe, C. 2006. The potential of oligonucleotides for therapeutic applications 24.
- Fleige, S., Pfaffl, M.W. 2006. RNA integrity and the effect on the real-time qRT-PCR performance. *Mol. Aspects Med.* 27: 126–139.
- Fukuda, M. 2013. Rab27 effectors, pleiotropic regulators in secretory pathways. *Traffic* 14: 949–63.
- Gajos-Michniewicz, A., Duechler, M., Czyz, M. 2014. MiRNA in melanoma-derived exosomes. *Cancer Lett.* 347: 29–37.
- Ganta, S., Devalapally, H., Shahiwala, A., Amiji, M. 2008. A review of stimuli-responsive nanocarriers for drug and gene delivery 126: 187–204.

- Geiger, T.R., Peeper, D.S. 2009. Metastasis mechanisms. *Biochim. Biophys. Acta - Rev. Cancer* 1796: 293–308.
- Gerber, D.E. 2008. Targeted therapies: A new generation of cancer treatments. *Am. Fam. Physician* 77: 311–319.
- Global Cancer Society 2008. 1–57.
- GLOBOCAN 2012. Int. Agency Research Cancer, World Heal. Organ. URL <http://globocan.iarc.fr/Default.aspx> (accessed 8.9.15).
- Grant, B.D., Donaldson, J.G. 2011. Pathways and mechanisms of endocytic recycling. *Nat Rev Mol Cell Biol* 10: 597–608.
- Grivennikov, S.I., Greten, F.R., Karin, M. 2011. Immunity, Inflammation, and Cancer. *Cell* 140: 883–899.
- Hanahan, D., Weinberg, R. a. 2011. Hallmarks of cancer: The next generation. *Cell* 144: 646–674.
- Hannafon, B.N., Ding, W.Q. 2013. Intercellular communication by exosome-derived microRNAs in cancer. *Int. J. Mol. Sci.* 14: 14240–14269.
- Heath, J.R., Davis, M.E. 2008. Nanotechnology and cancer. *Annu. Rev. Med.* 59: 251–65.
- Henderson, M.C., Azorsa, D.O. 2012. The Genomic and Proteomic Content of Cancer Cell-Derived Exosomes. *Front. Oncol.* 2: 1–9.
- Hendrix, A., de Wever, O. 2013. Rab27 GTPases distribute extracellular nanomaps for invasive growth and metastasis: Implications for prognosis and treatment. *Int. J. Mol. Sci.* 14: 9883–9892.
- Herceg, Z., Hainaut, P. 2007. Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosis. *Mol. Oncol.* 1: 26–41.
- Holliday, D.L., Speirs, V. 2011. Choosing the right cell line for breast cancer research. *Breast Cancer Res.* 13: 215.
- Hurley, J.H., Hanson, P.I. 2010. Membrane budding and scission by the ESCRT machinery: it's all in the neck. *Nat. Rev. Mol. Cell Biol.* 11: 556–566.
- Ikehata, H., Ono, T. 2011. The mechanisms of UV mutagenesis. *J. Radiat. Res.* 52: 115–125.
- Jain, P.K., El-Sayed, I.H., El-Sayed, M.A. 2007. Au nanoparticles target cancer. *Nanotoday.*
- Johnstone, R.M. 2006. Exosomes biological significance: A concise review. *Blood Cells. Mol. Dis.* 36: 315–21.
- Johnstone, R.M., Adam, M., Hammond, J.R., Orr, L., Turbide, C. 1987. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). *J. Biol. Chem.* 262: 9412–9420.
- Kahlert, C., Kalluri, R. 2013. Exosomes in tumor microenvironment influence cancer progression and metastasis. *J. Mol. Med.* 91: 431–437.
- Katoh, M. 2013. Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review). *Int. J. Mol. Med.* 32: 763–767.
- Keller, S., Sanderson, M.P., Stoek, A., Altevogt, P. 2006. Exosomes: From biogenesis and secretion to biological function. *Immunol. Lett.* 107: 102–108.
- Kharaziha, P., Ceder, S., Li, Q., Panaretakis, T. 2012. Tumor cell-derived exosomes: A message in a bottle. *Biochim. Biophys. Acta - Rev. Cancer* 1826: 103–111.

- King, H.W., Michael, M.Z., Gleadle, J.M. 2012. Hypoxic enhancement of exosome release by breast cancer cells. *BMC Cancer* 12: 421.
- Koga, K., Matsumoto, K., Akiyoshi, T., Kubo, M., Yamanaka, N., Tasaki, A., Nakashima, H., Nakamura, M., Kuroki, S., Tanaka, M., Katano, M. 2005. Purification, Characterization and Biological Significance of Tumor-derived Exosomes 3708: 3703–3707.
- Kucharzewska, P., Belting, M. 2013. Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. *J. Extracell. vesicles* 2: 1–10.
- Lee, C., Meisel, D. 1982. Adsorption and Surface-Enhanced Raman of Dyes on Silver and Gold Sols' 60439: 3391–3395.
- Levine, A.J., Puzio-Kuter, A.M. 2010. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. *Science* 330: 1340–1344.
- Lim, J., Yeap, S.P., Che, H.X., Low, S.C. 2013. Characterization of magnetic nanoparticle by dynamic light scattering. *Nanoscale Res. Lett.* 8: 1.
- Liu, Y., Shipton, M.K., Ryan, J., Kaufman, E.D., Franzen, S., Feldheim, D.L. 2007. Synthesis, Stability, and Cellular Internalization of Gold Nanoparticles Containing Mixed Peptide - Poly (ethylene glycol) Monolayers 79: 2221–2229.
- Livak, K.J., Schmittgen, T.D. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25: 402–408.
- Madhani, H.D., Guthrie, C. 1992. A novel base-pairing interaction between U2 and U6 snRNAs suggests a mechanism for the catalytic activation of the spliceosome. *Cell* 71: 803–817.
- Marleau, A.M., Chen, C.-S., Joyce, J. a, Tullis, R.H. 2012. Exosome removal as a therapeutic adjuvant in cancer. *J. Transl. Med.* 10: 134.
- Martins, P., Rosa, D., Fernandes, A.R., Baptista, P. V 2014. Nanoparticle Drug Delivery Systems: Recent Patents and Applications in Nanomedicine. *Recent Patents Nanomed.* 3.
- Mathivanan, S., Ji, H., Simpson, R.J. 2010. Exosomes: Extracellular organelles important in intercellular communication. *J. Proteomics* 73: 1907–1920.
- Mellman, I. 1996. Endocytosis and molecular sorting. *Annu. Rev. Cell Dev. Biol.* 12: 575–625.
- Mendelsohn, J. 2013. Personalizing oncology: perspectives and prospects. *J. Clin. Oncol.* 31: 1904–1911.
- Miller, D.M., Thomas, S.D., Islam, A., Muench, D., Sedoris, K. 2013. c-Myc and Cancer Metabolism 18: 5546–5553.
- Millipore 2012. Amicon® Ultra-4 Centrifugal Filter Devices 1–12.
- Muller, L., Hong, C.S., Stolz, D.B., Watkins, S.C., Whiteside, T.L. 2014. Isolation of biologically-active exosomes from human plasma. *J. Immunol. Methods.*
- Muralidharan-Chari, V., Clancy, J.W., Sedgwick, A., D'Souza-Schorey, C. 2010. Microvesicles: mediators of extracellular communication during cancer progression. *J. Cell Sci.* 123: 1603–1611.
- Nickels, S., Truong, T., Hein, R., Stevens, K., Buck, K., Behrens, S., Eilber, U., Schmidt, M., 2013. Evidence of Gene-Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. *PLoS Genet.* 9.
- Ostrowski, M., Carmo, N.B., Krumeich, S., Fanget, I., Raposo, G., Savina, A., Moita, C.F., Schauer,

- K., Hume, A.N., Freitas, R.P., Goud, B., Benaroch, P., Hacoheh, N., Fukuda, M., Desnos, C., Seabra, M.C., Darchen, F., Amigorena, S., Moita, L.F., Thery, C. 2010. Rab27a and Rab27b control different steps of the exosome secretion pathway. *Nat. Cell Biol.* 12: 19–30; sup pp 1–13.
- Park, M.-T., Lee, S.-J. 2003. Cell cycle and cancer. *J. Biochem. Mol. Biol.* 36: 60–65.
- Patel, P.C., Giljohann, D. a, Seferos, D.S., Mirkin, C. a 2008. Peptide antisense nanoparticles. *Proc. Natl. Acad. Sci. U. S. A.* 105: 17222–17226.
- Philip, D. 2008. Synthesis and spectroscopic characterization of gold nanoparticles. *Spectrochim. Acta. A. Mol. Biomol. Spectrosc.* 71: 80–5.
- Raposo, G., Stoorvogel, W. 2013. Extracellular vesicles: Exosomes, microvesicles, and friends. *J. Cell Biol.* 200: 373–383.
- Record, M., Carayon, K., Poirot, M., Silvente-Poirot, S. 2014. Exosomes as new vesicular lipid transporters involved in cell-cell communication and various pathophysiologicals. *Biochim. Biophys. Acta - Mol. Cell Biol. Lipids* 1841: 108–120.
- Record, M., Subra, C., Silvente-Poirot, S., Poirot, M. 2011. Exosomes as intercellular signalosomes and pharmacological effectors. *Biochem. Pharmacol.* 81: 1171–1182.
- Riches, A., Campbell, E., Borger, E., Powis, S. 2014. Regulation of exosome release from mammary epithelial and breast cancer cells-A new regulatory pathway. *Eur. J. Cancer* 50: 1025–1034.
- Roma-Rodrigues, C., Fernandes, A.R., Baptista, P.V. 2014. Exosome in tumour microenvironment: Overview of the crosstalk between normal and cancer cells. *Biomed Res. Int.* 2014.
- Rosa, J., Conde, J., de la Fuente, J.M., Lima, J.C., Baptista, P. V 2012. Gold-nanobeacons for real-time monitoring of RNA synthesis. *Biosens. Bioelectron.* 36: 161–7.
- Sanvicens, N., Marco, M.P. 2008. Multifunctional nanoparticles--properties and prospects for their use in human medicine. *Trends Biotechnol.* 26: 425–33.
- Sanz, V., Conde, J., Hernández, Y., Baptista, P. V., Ibarra, M.R., de la Fuente, J.M. 2012. Effect of PEG biofunctional spacers and TAT peptide on dsRNA loading on gold nanoparticles. *J. Nanoparticle Res.* 14: 917.
- Schiller, J.T., Lowy, D.R. 2014. *Viruses and Human Cancer* 193: 1–10.
- Silva, J., Fernandes, A.R., Baptista, P. V 2014. Application of Nanotechnology in Drug Delivery 14–17.
- Singh, R., Pochampally, R., Watabe, K., Lu, Z., Mo, Y.-Y. 2014. Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. *Mol. Cancer* 13: 256.
- Soekmadji, C., Russell, P.J., Nelson, C.C. 2013. Exosomes in prostate cancer: putting together the pieces of a puzzle. *Cancers (Basel).* 5: 1522–44.
- Sperling, R. a, Parak, W.J. 2010. Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. *Philos. Trans. A. Math. Phys. Eng. Sci.* 368: 1333–83.
- Suetsugu, A., Honma, K., Saji, S., Moriwaki, H., Ochiya, T., Hoffman, R.M. 2013. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. *Adv. Drug Deliv. Rev.* 65: 383–90.
- SV Total RNA Isolation System 2009 . Promega.
- Svensson, K.J., Christianson, H.C., Wittrup, A., Bourseau-Guilmain, E., Lindqvist, E., Svensson, L.M., Mörgelin, M., Belting, M. 2013. Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid raft-mediated endocytosis negatively regulated by caveolin-1. *J. Biol. Chem.*


288: 17713–17724.

- Tan, A., Rajadas, J., Seifalian, A.M. 2013. Exosomes as nano-theranostic delivery platforms for gene therapy. *Adv. Drug Deliv. Rev.* 65: 357–367.
- Théry, C., Clayton, A., Amigorena, S., Raposo, G. 2006. Isolation and characterization of exosomes from cell culture supernatants, in: *Current Protocols in Cell Biology*. pp. 3.22.1–3.22.29.
- Théry, C., Zitvogel, L., Amigorena, S. 2002. Exosomes: composition, biogenesis and function. *Nat. Rev. Immunol.* 2: 569–79.
- Trams, E.G., Lauter, C.J., Salem, N., Heine, U. 1981. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. *Biochim. Biophys. Acta* 645: 63–70.
- Tran, T.-H., Mattheolabakis, G., Aldawsari, H., Amiji, M. 2015. Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases, *Clinical Immunology*. Elsevier B.V.
- Turkevich, J., Stevenson, P.C., Hillier, J. 1951. A study of the nucleation and growth processes in the synthesis of Colloidal Gold. *Discuss. Faraday Soc.* 11: 55–75.
- Urbanelli, L., Magini, A., Buratta, S., Brozzi, A., Sagini, K., Polchi, A., Tancini, B., Emiliani, C. 2013. Signaling pathways in exosomes biogenesis, secretion and fate. *Genes (Basel)*. 4: 152–170.
- Vaiselbuh, S.R. 2015. Exosomes in Cancer Research 1: 11–24.
- Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J.J., Lötvall, J.O. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.* 9: 654–9.
- van der Pol, E., Böing, A.N., Harrison, P., Sturk, A., Nieuwland, R. 2012. Classification, functions, and clinical relevance of extracellular vesicles. *Pharmacol. Rev.* 64: 676–705.
- Villarroya-Beltri, C., Baixauli, F., Gutiérrez-Vázquez, C., Sánchez-Madrid, F., Mittelbrunn, M. 2014. Sorting it out: Regulation of exosome loading. *Semin. Cancer Biol.* 1–11.
- Vlassov, A. V., Magdaleno, S., Setterquist, R., Conrad, R. 2012. Exosomes: Current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. *Biochim. Biophys. Acta - Gen. Subj.* 1820: 940–948.
- Waldmann, T., Schneider, R. 2013. Targeting histone modifications - epigenetics in cancer. *Curr. Opin. Cell Biol.* 25: 184–189.
- Wang, J.-S., Wang, F.-B., Zhang, Q.-G., Shen, Z.-Z., Shao, Z.-M. 2008. Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II. *Mol. Cancer Res.* 6: 372–382.
- WHO 2015. . World Heal. Organ. URL <http://www.who.int/> (accessed 8.3.15).
- World Cancer Report 2008. , in: *World Cancer Report*. pp. 97–133.
- Yellon, D.M., Davidson, S.M. 2014. Exosomes: nanoparticles involved in cardioprotection? *Circ. Res.* 114: 325–332.
- Zhang, H.G., Grizzle, W.E. 2014. Exosomes: A novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. *Am. J. Pathol.* 184: 28–41.
- Zhang, J., Li, S., Li, L., Li, M., Guo, C., Yao, J., Mi, S. 2015. Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function. *Genomics. Proteomics Bioinformatics* 13: 17–24.

- Zhang, M.-Z., Li, C., Fang, B.-Y., Yao, M.-H., Ren, Q.-Q., Zhang, L., Zhao, Y.-D. 2014. High transfection efficiency of quantum dot-antisense oligonucleotide nanoparticles in cancer cells through dual-receptor synergistic targeting. *Nanotechnology* 25: 255102.
- Zhang, W., Kai, K., Ueno, N.T., Qin, L. 2013. A Brief Review of the Biophysical Hallmarks of Metastatic Cancer Cells. *Cancer Hallm.* 1: 59–66.


## 6 APPENDICES

### APPENDIX A




**Figure A 1: Coverage of AuNP surface with PEG.** A) Absorbance spectra of DTNB after reaction with PEG. B) Calibration curve for PEG chains. Concentration can be calculated with the equation  $Abs_{412\text{ nm}} = 921x + 9,0378$ , being  $x = [\text{PEG}, \text{mg/mL}]$ . C) Variation of PEG concentration incubated with AuNPs. It is shown that the 100% saturation point is obtained with 0.01mg/mL of PEG and above that no more PEG can bound to the AuNP's surface.





**Figure A 2: Oligonucleotide quantification.** Calibration curve obtained from fluorescence spectra. The amount of fluorophore-labelled oligonucleotides present in the supernatant can be determined using the following equation:  $Y = 6124,9x + 74,97$  ( $R^2 = 0,9904$ ).

APPENDIX B



**Figure A 3: Characterization of gold nanoparticles by TEM.** A) TEM images of naked AuNPs; B) TEM images of AuNP@PEG; C) Histogram with size distribution of naked AuNPs D) Histogram with size distribution of AuNP@PEG.